СПОСОБ И УСТРОЙСТВО ДЛЯ СОЗДАНИЯ ОБОЛОЧКИ СТЕНТА

Изобретение относится к медицине, а именно к хирургии. Изобретение обеспечивает снижение развития рестеноза при возможности увеличения диаметра системы доставки стента, необходимого для доставки стента данного диаметра в раскрытом виде. Раскрывающийся стент, пригодный для имплантации в сосуд, покрывается биологическим материалом. В одном варианте использования изобретения биологические волокна переплетаются таким образом, что указанные волокна образуют покрытие указанного стента. Указанные волокна располагаются под углом относительно продольной оси указанного стента, причем при раскрытии указанного стента указанный угол увеличивается. В другом варианте использования изобретения полоса перикарда спирально наматывается на поддерживающий стент, когда указанный стент находится в нераскрытом состоянии. При раскрытии указанного стента полоса разматывается, при этом сохраняя полное покрытие поверхности стента. С целью сохранения полного покрытия поверхности стента на полосе могут быть образованы ...

ПОДЛОЖКА С ЭЛЕКТРОНОДОНОРНОЙ ПОВЕРХНОСТЬЮ, СОДЕРЖАЩЕЙ ЧАСТИЦЫ МЕТАЛЛА, ВКЛЮЧАЯ ПАЛЛАДИЙ

Изобретение относится к медицине. Описана подложка, имеющая электронодонорную поверхность, на которой имеются металлические частицы, содержащие палладий и по меньшей мере один металл, выбранный из группы, состоящей из золота, рутения, родия, осмия, иридия и платины, причем количество указанных металлических частиц составляет примерно от 0,001 до 8 мкг/см2. Примерами изделий с подобным покрытием являются контактные линзы, стимуляторы сердца, электроды для стимуляторов сердца, стенты, зубные имплантаты, грыжевые сетки и ячеистые структуры, оборудование для центрифугирования крови, хирургические инструменты и другие. Модифицируют поверхностные свойства подложки, влияющие на ее биосовместимость и антимикробные свойства. 4 н. и 14 з.п. ф-лы, 4 табл.

Способ покрытия герниоимплантата с использованием аскорбиновой кислоты

Изобретение относится к медицине, а именно хирургии грыж передней брюшной стенки. Способ покрытия герниоимплантата с использованием аскорбиновой кислоты, включает использование метилцеллюлозы. Берут 96 массовых долей очищенной воды комнатной температуры 20-25°С и делят на две половины, каждая из которых была равна 48 массовым долям, затем взвешенный порошок полимера метилцеллюлозы массовой долей 2,0 в асептических условиях заливают в первой половине 48 массовых долей горячей воды нагретой до 80-90°С и оставляют на 2 часа до набухания и растворения полимера, далее во второй половине 48 массовых долей очищенной воды комнатной температуры растворяют 2,0 массовыми долями аскорбиновой кислоты, затем раствор аскорбиновой кислоты добавляют к раствору метилцеллюлозы, и полученный раствор для деаэрации помещают в пробирку и центрифугируют 5 мин, полученный деаэрированный раствор выливают в чашку Петри и помещают в нее синтетический имплантат для иммобилизации на 1 час, иммобилизованную композицию ...

СПОСОБ ЭНДОТЕЛИЗАЦИИ ПРОТЕЗОВ КРОВЕНОСНЫХ СОСУДОВ

Группа изобретений относится медицине, в частности к способу нанесения несплошного покрытия из металла, выбранного из титана, циркония, гафния, ванадия, ниобия или тантала, на внутреннюю и внешнюю поверхность полимерного протеза кровеносного сосуда из полиэтилентерефталата; а также к протезу кровеносного сосуда, содержащему каркас из полиэтилентерефталата с нанесенным несплошным покрытием из металла. Осуществление изобретения позволяет сократить время образования неоинтимы по всей внутренней поверхности протеза кровеносного сосуда за счет технологии нанесения несплошного покрытия на внутреннюю или внешнюю поверхность протеза. 2 н. и 10 з.п. ф-лы, 1 табл., 5 ил.

ВОССТАНОВЛЕНИЕ КРОВОТОКА В ЗАБЛОКИРОВАННЫХ АРТЕРИЯХ ЧЕЛОВЕКА ПУТЕМ ПЕРЕНОСА НАНОИНКАПСУЛИРОВАННОГО ЛЕКАРСТВЕННОГО СРЕДСТВА ПОСРЕДСТВОМ МЕДИЦИНСКИХ УСТРОЙСТВ, РАЗРАБОТАННЫХ ДЛЯ ЭТОГО, И ВЫСВОБОЖДЕНИЯ НАНОИНКАПСУЛИРОВАННОГО СРЕДСТВА В АРТЕРИИ ЧЕЛОВЕКА ПРИ УРОВНЕ pН ОРГАНИЗМА

... 1. Доставляющее лекарственное средство вводимое медицинское устройство для лечения медицинского состояния, связанного с просветом части организма, при этом просвет части организма имеет границы с множеством слоев, причем доставляющее лекарственное средство вводимое медицинское устройство имеет:внешнюю поверхность, покрытую множеством наноносителей, имеющих множество средних диаметров, при этом наноноситель из множества наноносителей содержит лекарственное средство, окруженное инкапсулирующей средой, где инкапсулирующая среда содержит по меньшей мере одно из биологического средства, наполнителя на основе крови и фосфолипида, при этом наноноситель имеет средний диаметр, приемлемый для проникновения сквозь по меньшей мере один слой из множества слоев, и поверхность наноносителя свободна от лекарственного средства.2. Доставляющее лекарственное средство вводимое медицинское устройство по п.1, где множество наноносителей высвобождаются с внешней поверхности, и по меньшей мере один наноноситель ...

Chirurgisches Implantat

Ein chirurgisches Implantat hat eine Grundstruktur mit einer zumindest teilweisen Beschichtung. Das Implantat weist alpha-Hydroxycarbonsäure-Oligomere (vorzugsweise Milchsäure-Oligomere) auf und/oder lässt diese nach der Implantation als Abbauprodukt entstehen. Die Beschichtung enthält Polyolmonofettsäureester, vorzugsweise Glycerinmonofettsäureester. Das Implantat wirkt antimikrobiell.

Implant for e.g. releasing active substances into a vessel through which body fluids flow, comprises a base consisting of a biodegradable material as the carrier of the active substances

An implant (I), to release an active substance (a) into a vessel through which body fluids flow, comprises a base consisting of a biodegradable material as the carrier of (a), where the body fluids flow around, inside and/or outside the base. ACTIVITY : Cytostatic. MECHANISM OF ACTION : None given.

Novel process and products

Coated Medical devices

Regulation/modification of stent contact surface for polymer free drug coating

Bio-degradable/absorbable barrier membrane

Textile products having a sealant or coating and method of manufacture

BIOCOMPATIBLE, BIOSTABLE COATING OF MEDICAL SURFACES

MEDICINE PRODUCTS WITH SEVERAL LOADED LAYERS

BIODEGRADABLE MEDICAL DEVICES WITH IMPROVED MECHANICAL FIRMNESS AND PHARMAKOLOGI FUNCTION

BIOLOGICALLY ABLATABLE ENDOPROSTHESES

OSTEOSYNTHETI ARTICLES WITH SURFACE-COATED BONE CONTACT SURFACES.

PROCEDURE FOR THE PRODUCTION OF BIOACTIVE IMPLANT SURFACES

INITIATIONSGRUPPENTRAGENDES WATER-SOLUBLE COATING MEANS AND COATING PROCESS

MATERIALS AND METHODS FOR CONTROLLING INFECTIONS

The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to 5 be possible.

Method of removing a stylette from a catheter

A hydrophilic coated stylette is pre-loaded in an implantable catheter. The hydrophilic coated stylette is wetted with saline to activate the hydrophilic coating. 5 The stylette loaded catheter is tunneled, typically through muscle and tissue, to a desired target site within the body. The hydrophilic coated stylette is then removed from the catheter while maintaining the catheter intact. The proximal end of the catheter can be connected to an outlet of an implantable infusion pump so that medicament can be delivered directly to the target site. 18/10/06,16109 specification,2 U-( L -~L0 ...

A micro-RNA family that modulates fibrosis and uses thereof

Anchorage devices comprising an active pharmaceutical ingredient

An anchorage device 100 comprising a mesh substrate 124 coupled to an implantable medical device 120 is disclosed, where the mesh substrate has a coating 120 comprising a polymer, and the mesh further comprises at least one active pharmaceutical ingredient. The active pharmaceutical agent is designed to elute from the device over time. The mesh substrate can be configured to reduce the mass of the anchorage device such that tissue in-growth and/or scar tissue formation at the treatment site is reduced. In some embodiments, the mesh substrate can be formed with a mesh having a low areal density. In some embodiments, the mesh substrate can include one or more apertures or pores to reduce the mass of the substrate.

Bio-compatible polymeric materials

Gold (I)-phosphine compounds as anti-bacterial agents

A compound of formula (I): for use in the prevention or treatment of a bacterial infection wherein: A is either S or Se; RA is selected from: wherein: each of Y ...

Materials and methods for controlling infections

The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.

Method for immobilizing mediator molecule on inorganic and metal implant material

Method and apparatus for covering a stent

MEDICAL DEVICE HAVING A COATING LAYER WITH STRUCTURAL ELEMENTS THEREIN AND METHOD OF MAKING THE SAME

COATING MEDICAL DEVICES USING AIR SUSPENSION

Methods and apparatuses for coating medical devices and the devices thereby produced are disclosed. In one embodiment, the invention includes a method comprising the steps of suspending the medical device in an air stream and introducing a coating material into the air stream such that the coating material is dispersed therein and coats at least a portion of the medical device. In another embodiment, the medical devices are suspended in an air stream and a coating apparatus coats at least a portion of the medical device with a coating material. The coating apparatus may include a device that utilizes any number of alternative coating techniques for coating the medical devices. This process is used to apply one or more coating materials, simultaneously or in sequence. In certain embodiments of the invention, the coating materials include therapeutic agents, polymers, sugars, waxes, or fats. By using air suspensions to coat medical devices, the methods of the present invention result in coatings ...

USES OF CYANOBACTERIUM EXTRACELLULAR POLYMER, COMPOSITIONS, COATED SURFACES OR ARTICLES

The present disclosure relates to a coating with anti-adhesive properties (in order to repel or prevent bacterial or platelet adhesion) based on a naturally produced polymer. This polymer that has been extensively characterized and is produced by a marine bacterium -Cyanothece sp. CCY 0110, at optimized production conditions to obtain increased amounts of polymer. Importantly, this strain is among the highly efficient polymer producers, secreting the polymer directly to the media, allowing the easy recovery of polymer with few purification steps, being a cost-effective product. The coating can be applied to medical devices or medical implants to prevent biofilm mediated infections thereof.

CROSS-LINKED RADIOPAQUE BIORESORBABLE POLYMERS AND DEVICES MADE THEREFROM

The present application provides polymer materials having the desired properties for implantation into a human or animal body, in particular, biocompatibility, biodegradability, radiopacity and mechanical properties. Methods of making such polymer materials, compositions or devices comprising such polymer materials, and uses of such polymer materials, compositions and devices are also disclosed.

DRUG COMPOSITION AND COATING

According to the invention there is provided inter aliaa medical device for delivering a paclitaxel to a tissue, the device the device having a coating layer applied to a surface of the device, the coating layer comprising components i), ii) and iii), wherein component i) is a therapeutic agent which is paclitaxel; and component ii) is urea or a pharmaceutically acceptable salt thereof, or a urea derivative or a pharmaceutically acceptable salt thereof; and component iii) is succinic acid,glutaricacidor caffeine, or a pharmaceutically acceptable salt of any one thereof.

ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE

Disclosed herein are novel peptides that can comprise antimicrobial, antiviral, antifungal or antitumor activity when administered to a subject.

MEDICAL DEVICE HAVING A LUBRICANT

A medical device includes a member (210) , a coating (220) , and a lubricant (230) . In one embodiment, the coating includes a therapeutic agent. In one embodiment, the coating is disposed on at least a portion of the body and the lubricant is disposed on at least a portion of the coating. In one embodiment, the lubricant is formulated to provide an effective degree of lubricity between the coating and at least one of a surface of a package configured to receive at least a portion of the medical device, another portion of the medical device, a coating of another medical device, and an uncoated portion of another medical device. In one embodiment, the lubricant is soluble in at least one of water and a bodily fluid of a mammal. In one embodiment, the coating is formulated to release from the member when the medical device is placed within a body of a patient.

A SUBSTRATE HAVING AN ELECTRON DONATING SURFACE WITH METAL PARTICLES COMPRISING PALLADIUM ON SAID SURFACE

There is disclosed a substrate with an electron donating surface, characterized in having metal particles on said surface, said metal particles comprising palladium and at least one metal selected from the group consisting of gold, ruthenium, rhodium, osmium, iridium, and platinum, wherein the amount of said metal particles is from about 0.001 to about 8µg/cm2. Examples of coated objects include contact lenses, pacemakers, pacemaker electrodes, stents, dental implants, rupture nets, rupture mesh, blood centrifuge equipment, surgical instruments, gloves, blood bags, artificial heart valves, central venous catheters, peripheral venous catheters, vascular ports, haemodialysis equipment, peritoneal dialysis equipment, plasmapheresis devices, inhalation drug delivery devices, vascular grafts, arterial grafts, cardiac assist devices, wound dressings, intermittent catheters, ECG electrodes, peripheral stents, bone replacing implants, orthopaedic implants, orthopaedic devices, tissue replacing ...

HYDROPHOBIC CROSS-LINKED GELS FOR BIOABSORBABLE DRUG CARRIERCOATINGS

NOVEL COATINGS FOR MEDICAL DEVICES

The present invention is directed to improved coatings and coating methods for medical devices.

DRUG FLUTING MEDICAL DEVICE

The present disclosure relates to medical devices, and methods for producing and using the devices. In embodiments, the medical device may be a buttress including a porous substrate possessing a therapeutic layer of a chemotherapeutic agent and optional excipient(s) thereon. By varying the form of chemotherapeutic agents and excipients, the medical devices may be used to treat both the area to which the medical device is attached as well as tissue at a distance therefrom.

CONTINUOUS-FIBER REINFORCED BIOCOMPOSITE MEDICAL IMPLANTS

A medical implant comprising a plurality of layers, each layer comprising a polymer and a plurality of uni-directionally aligned continuous reinforcement fibers.

ORIENTED P4HB IMPLANTS CONTAINING ANTIMICROBIAL AGENTS

Oriented resorbable implants made from poly-4-hydroxybutyrate (P4HB) and copolymers thereof, have been developed that contain one or more antimicrobial agents to prevent colonization of the implants, and reduce or prevent the occurrence of infection following implantation in a patient. These oriented implants are particularly suitable for use in procedures where prolonged strength retention is necessary and there is a risk of infection. Coverings and receptacles made from poly-4- hydroxybutyrate and copolymers thereof, containing antimicrobial agents, have also been developed for use with implantable devices to prevent colonization of these devices, and to reduce or prevent the occurrence of infection following implantation of these devices in a patient. These coverings and receptacles may be used to hold, or partially or fully cover, devices such as pacemakers and neurostimulators. Preferably, the coverings and receptacles are made from meshes, non-wovens, films, fibers, and foams, and ...

N-HALAMINE CONTAINING FIBROUS COMPOSITIONS AND USES THEREOF

The present disclosure provides fibrous composition comprising a soluble or a dispersible N-halamine, for example 1-chloro-2,2,5,5-tetramethyl-4-imidazolidinone (i.e., compound I). Additionally, the disclosure provides methods for producing the fibrous compositions comprising a soluble or a dispersible N-halamine as well as methods for protecting a person from an infection using the fibrous compositions comprising a soluble or a dispersible N-halamine. The compositions and methods according to the present disclosure provide several advantages, such as stability, less time to provide sufficient antimicrobial inactivation, and are inexpensive and require lower amount of active concentrations to be effective.

ANTIBACTERIAL MEDICINAL PRODUCT AND METHOD FOR PRODUCING SAME

The invention relates to a medicinal product, comprising an antibacterial hard material coating, which is applied to a main body and which comprises biocide. Said hard material coating includes at least one inner layer and one outer layer, wherein the biocide concentration in the outer layer is substantially constant and greater than the biocide concentration in the inner layer and the biocide concentration in the inner layer is greater than or equal to 0.2 at%.

COMPOSITION FOR FORMING A TEMPORARY INTESTINAL OCCLUSION IN A MAMMAL

The invention relates to a composition for producing a temporary obstruction of the intestine of a mammal, wherein the composition is flowable and can be solidified at a desired location in the intestine to form a solid plug, the structure of which can be modified for the subsequent, at least partial removal of the obstruction, wherein the composition is or comprises a flowable solution, suspension or dispersion in a solvent or solvent mixture, characterised in that the composition comprises the following: a) a suspension of a solid in water or in an aqueous solvent mixture having a content of water that is an amount X above the liquid limit of the suspension; b) a dehydrating agent in an amount sufficient to bind the amount X of water such that the liquid limit of the suspension is exceeded as a result of the dehydration; and c) an agent for passivating the dehydrating agent.

DRUG DELIVERY SYSTEM AND METHOD OF MANUFACTURING THEREOF

An apparatus and method provides a drug layer formed on a surface region of a medical device, the drug layer comprised of a drug deposition and a carbonized or densified layer formed from the drug deposition by irradiation on an outer surface of the drug deposition, wherein the carbonized or densified layer does not penetrate through the drug deposition and is adapted to release drug from the drug deposition at a predetermined rate.

DRUG DELIVERY SYSTEM AND METHOD OF MANUFACTURING THEREOF

An apparatus and method provides a drug layer formed on a surface region of a medical device, the drug layer comprised of a drug deposition and a carbonized or densified layer formed from the drug deposition by irradiation on an outer surface of the drug deposition, wherein the carbonized or densified layer does not penetrate through the drug deposition and is adapted to release drug from the drug deposition at a predetermined rate.

MOLECULES AND METHODS FOR INHIBITION AND DETECTION OF PROTEINS

The present application belongs to the field of functional peptides and more particularly to the field of controlled protein aggregation. The invention discloses molecules of a peptide structure as defined in the claims and methods of using such molecules for therapeutic applications and for diagnostic uses, as well as in other applications such as in the agbio field and in industrial biotechnology. The molecules can be used for curing and/or stabilizing infections such as bacterial,fungal and viral diseases, but are also useful in non-infectious human and veterinary diseases. The molecules can also be used for the detection of protein biomarkers and for the prognosis and diagnosis of a variety of diseases.

COATING COMPOSITION AND MEDICAL DEVICE

The present invention provides a coating composition for drug eluting medical devices, which enables a medical device to be delivered to a target tissue without having a medical agent easily separated from the medical device on the way to the target tissue for the purpose of treating an affected blood vessel such as restenosis. This coating composition for drug eluting medical devices contains a water-insoluble medical agent and at least one substance that is selected from the group consisting of ester compounds of amino acids, which have a hydrophobicity index of an amino acid side chain of 0 or less, and salts thereof.

VAPOR HYDRATED MEDICAL DEVICE WITH LOW SURFACE ENERGY SLEEVE

A medical device such as a catheter in a liquid and vapor impermeable package, the device being contained in a low surface energy sleeve or compartment that is liquid impermeable and vapor permeable. Water vapor molecules from a liquid provided within the package exteriorly of the sleeve or compartment migrate across the sleeve or compartment to an interior thereof, thereby creating and maintaining a moist environment for the device, which may include activating a hydrophilic coating of the catheter. Water molecules are transported through the sleeve from an exterior of the sleeve or compartment to the interior of the sleeve compartment. Upon removal of the device from the package, the exterior of the sleeve or compartment is drier to the touch.

MEDICAL DEVICES WITH LONG TERM NON-THROMBOGENIC COATINGS

A coating and method for implantable open lattice metallic stent prostheses are disclosed. The coating includes a relatively thin layer of biostable elastomeric material containing an amount of biologically active material particularly heparin, dispersed in the coating in combination with a non-thrombogenic surface. In one embodiment, the surface is provided with sites of high electronegativity species by coating with fluorosilicone which aid in controlling elution, particularly the initial release rate, and reduced thrombogenic activity. Other non-thrombogenic outer layers for heparin such as covalently bound polyethylene glycol (PEG) are also disclosed.

Barrier membrane biodegradable and/or bioabsorbable.

A Micro-RNA Family That Modulates Fibrosis and Uses Thereof

... 본 발명은 심장 조직에서 섬유증의 주요 조절제인 지정된 miR-29a-c인 microRNA 집단의 동정에 관한 것이다. 본 발명자들은 miR-29 집단의 구성원들은 스트레스에 반응하여 심장 조직에서 하강 조절되고 스트레스 및 섬유증에 저항력이 있는 생쥐의 심장 조직에서 상승 조절된다는 것을 입증하였다. 또한 심비대, 골격근 섬유증, 다른 섬유증 관련 질환 및 콜라겐 손실-관련 질환을 포함하는 섬유성 질환을 치료로서 miRNA의 miR-29 집단의 발현과 활성을 조절하는 방법을 제공한다.

composiÇÕes e mÉtodos para promover a cura de feridas e a regeneraÇço de tecidos

COMPOSITION FOR PRODUCING A TEMPORARY INTESTINAL OBSTRUCTION

The invention relates to a composition for producing a temporary obstruction of the intestine of a mammal, wherein the composition is flowable and can be solidified at a desired location in the intestine to form a solid plug, the structure of which can be modified for the subsequent, at least partial removal of the obstruction, wherein the composition is or comprises a flowable solution, suspension or dispersion in a solvent or solvent mixture, characterised in that the composition comprises the following: a) a suspension of a solid in water or in an aqueous solvent mixture having a content of water that is an amount X above the liquid limit of the suspension; b) a dehydrating agent in an amount sufficient to bind the amount X of water such that the liquid limit of the suspension is exceeded as a result of the dehydration; and c) an agent for passivating the dehydrating agent.

TISSUE REINFORCING COMPOSITIONS, DEVICES AND METHODS OF USE

Methods for manipulating and/or reinforcing tissues are provided. The method includes applying a tissue reinforcement material to at least a portion of tissue to be manipulated and applying energy to one or both of the tissue reinforcement material and the tissue.

MEDICAL DEVICES HAVING SURFACE COATINGS

According to an aspect of the present invention, medical devices are provided which comprise a metallic region and a coating on all or part of the metallic region that comprises a multivalent acid.

DRUG DELIVERY SYSTEM AND METHOD OF MANUFACTURING THEREOF

An apparatus and method provides a drug layer formed on a surface region of a medical device, the drug layer comprised of a drug deposition and a carbonized or densified layer formed from the drug deposition by irradiation on an outer surface of the drug deposition, wherein the carbonized or densified layer does not penetrate through the drug deposition and is adapted to release drug from the drug deposition at a predetermined rate.

COATING MEDICAL DEVICES USING AIR SUSPENSION

Cette invention a trait à des procédés et aux appareils correspondants permettant d'enrober des dispositifs médicaux ainsi qu'aux dispositifs médicaux ainsi produits. Dans un mode de réalisation, le procédé consiste à mettre le dispositif médical en suspension dans un courant d'air et à introduire un matériau d'enrobage dans ce courant d'air de sorte qu'il s'y disperse et enrobe au moins une partie du dispositif médical. Dans une autre réalisation, les dispositifs médicaux sont mis en suspension dans un courant d'air et un appareil d'enrobage enrobe au moins une partie du dispositif au moyen d'un matériau d'enrobage. L'appareil d'enrobage peut comporter un dispositif utilisant n'importe quel nombre de variantes de techniques d'enrobage pour enrober ces dispositifs médicaux. On utilise ce procédé pour appliquer un ou plusieurs matériaux d'enrobage, en même temps ou successivement. Dans certaines réalisations, les matériaux d'enrobage comportent des agents thérapeutiques, des polymères, des ...

METHOD OF COVERING A STENT WITH ACELLULAR MATRIX

A stent having an inner tubular lining of a biomaterial. The inner lining has open ends which may be rolled about the ends of the stent. The ends of the tube are then attached to the tube itself. Alternatively, the inner tube lining is attached directly to the stent. A method of covering a stent includes mounting a tube of biomaterial on a distal end of a catheter and mounting the stent over the biomaterial. The biomaterial may be seeded with endothelial cells.

RESIN COMPOSITION FOR PREVENTING ATTACHMENT OF AQUATIC ORGANISM OR PHYSIOLOGICAL SUBSTANCE

A resin composition for preventing the attachment of an aquatic organism or a physiological substance which comprises a hydrolyzable organic metal compound capable of imparting hydrophilic property to a surface and a resin as a binder; and a composition, a structure and a medical member prepared by using the resin composition, which are capable of preventing the attachment of an aquatic organism, a physiological substance and a hydrophobic stain and also are easy to remove stains therefrom.

Method for manufacturing a medical device having a coated portion by laser ablation

The present invention is directed to a method for manufacturing a medical device having a coated portion which comprises obtaining a structure having an inner surface and an outer surface; coating at least a portion of the inner or outer surface with a first coating material; and ablating the coated tubular structure with a laser to form at least one opening therein to form the coated portion. A plate can be used instead of the structure, and the plate is folded to form the structure after the ablation. A plurality of medical devices, made of any materials and having uniform coating(s), can be easily manufactured by the method of the present invention.

THERMAL SURGICAL TOOL

An electrical conductor, such as a wire or catheter, which is coated circumferentially with a ferromagnetic material in a selected region, is fed from a high frequency alternating current source. The ferromagnetic material has a quick response in heating and cooling to the controllable power delivery. The ferromagnetic material can be used for separating tissue, coagulation, tissue destruction or achieving other desired tissue effects in numerous surgical procedures.

STENTS MODIFIED WITH MATERIAL COMPRISING AMNION TISSUE AND CORRESPONDING PROCESSES

A stent scaffold combined with amniotic tissue provides for a biocompatible stent that has improved biocompatibility and hemocompatibility. The amnion tissue can be variously modified or unmodified form of amnion tissue such as non-cryo amnion tissue, solubilized amnion tissue, amnion tissue fabric, chemically modified amnion tissue, amnion tissue treated with radiation, amnion tissue treated with heat, or a combination thereof. Materials such as polymer, placental tissue, pericardium tissue, small intestine submucosa can be used in combination with the amnion tissue. The amnion tissue can be attached to the inside, the outside, both inside and outside, or complete encapsulation of the stent scaffold. In some embodiments, at least part of the covering or lining comprises a plurality of layers of amnion tissue. The method of making the biocompatible stent and its delivery and deployment are also discussed.

Ocular implants and methods for their manufacture

Application of a coating on a medical device

Devices for the provision of a coating on an implantable medical device are provided. The coating includes a bio-absorbable carrier component. In addition to the bio-absorbable carrier component, a therapeutic agent component can also be provided. The devices provide a coating having improved uniformity and coverage which in turn allow for greater control of the amount and dosage of the coating.

Method for coating implantable devices

Coating an implantable device, such as micro electromechanical devices, is highly desirable to protect the implantable device from corrosion. A coating method includes depositing, preferably by plasma glow discharge, a reactant monomer on at least one surface of an implantable device, preferably at ambient temperature. The method will likely decrease the manufacturing time required for assembling such devices because completely assembled devices can be coated.

Biocorrodable implant in which corrosion may be triggered or accelerated after implantation by means of an external stimulus

The present invention relates to a biocorrodable implant in which corrosion may be triggered or accelerated after implantation by applying an external stimulus, the implant having a base body which is completely or partially composed of a biocorrodable metallic material, and the base body having a coating with a protective layer which is not biocorrodable. According to the invention, the implant has control elements which are configured in such a way that the protective layer, optionally in combination with the control elements, completely or partially encloses the base body so as to be impermeable to bodily medium, and the protective layer being convertible to a form which is permeable to bodily medium as the result of a change in shape of the control elements which may be regulated and/or controlled by an external stimulus.

Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids

The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, at least one of an oil, a fatty acid, and a lipid, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, a part that has an affinity to the therapeutic agent by charge, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is at least one of a surfactant and a chemical compound. In further embodiments, the chemical compound is water-soluble.

REINFORCED POROUS COATING

ENDOPROSTHESES

ACID FUNCTIONALISED COATED MEDICAL DEVICE AND METHOD OF COATING SUCH A DEVICE

СТЕНТ С ТОНКИМИ КАРКАСНЫМИ ЭЛЕМЕНТАМИ ИЗ БИОРАССАСЫВАЮЩЕГОСЯ ПОЛИМЕРА С ВЫСОКОЙ УСТАЛОСТНОЙ И РАДИАЛЬНОЙ ПРОЧНОСТЬЮ И СПОСОБ ЕГО ИЗГОТОВЛЕНИЯ

Группа изобретений относится к медицине. Описан способ получения расширяемого баллоном стента, выполненного из биорассасывающегося полимера, с тонкими каркасными элементами, толщиной каркасных элементов, составляющей 130 мкм или менее, предпочтительно 100-110 мкм, с высокой усталостной и радиальной прочностью. Описан расширяемый баллоном стент, выполненный из биорассасывающегося полимера, с тонкими каркасными элементами, с толщиной каркасных элементов, составляющей 130 мкм или менее, предпочтительно 100-110 мкм, с высокой усталостной и радиальной прочностью. 2 н. и 16 з.п. ф-лы, 8 ил., 2 пр.

СПОСОБ НАНЕСЕНИЯ ПОКРЫТИЯ И ПОВЕРХНОСТЬ С ПОКРЫТИЕМ, ПОКРЫТИЕ И ИМПЛАНТ, СОДЕРЖАЩИЙ ТАКОЕ ПОКРЫТИЕ

Изобретение относится к способу нанесения покрытия на поверхность. Техническим результатом является улучшение несущей способности имплантов для использования, например, имплантов тазобедренных суставов. Технический результат достигается способом нанесения покрытия на поверхность, который включает следующие этапы. Абразивная обработка покрываемой поверхности частицами. Формирование и/или размещение на абразивно обработанной поверхности композитной структуры. Композитная структура содержит первое полотно из волокон, пропитанное первой смолой; пучок волокон, пропитанный второй смолой, расположенный в соответствии с рисунком, образующим промежуточные пространства, и в контакте с первым полотном из волокон; частицы биологически активного материала, размещенные в упомянутых промежуточных пространствах пучка волокон и размещенные в контакте с первым полотном из волокон; второе полотно из волокон, пропитанное третьей смолой, размещенное в контакте с пучком волокон и частицами биологически активного ...

УСТРОЙСТВО ДЛЯ ВЫДАЧИ ЛЕКАРСТВЕННОГО СРЕДСТВА, СПОСОБ ЕГО ИЗГОТОВЛЕНИЯ И ЕГО ПРИМЕНЕНИЕ

Изобретение относится к медицине и используется для выборочного лечения больных участков ткани или частей органов. Поверхность контактирующих с этими участками под давлением медицинских устройств покрывают липофильными, в значительной степени водонерастворимыми и связывающимися с любыми составными частями ткани лекарственными средствами, которые оказывают свое действие в соответствующем месте сразу же после контакта с тканью и очень короткое время и без вредного влияния на соседнюю здоровую ткань. Устройство включает баллон, с поверхностью которого сцеплены липофильные, водонерастворимые, связующиеся с тканью лекарственные средства. После контакта с тканью они имеют возможность мгновенно высвобождать биологически активные вещества. Баллон имеет предварительно формованные продольные складки. Биологически активное вещество покрывает закрытые складками участки баллона. 3 н. и 16 з.п. ф-лы.

АНТИБАКТЕРИАЛЬНОЕ МЕДИЦИНСКОЕ ИЗДЕЛИЕ И СПОСОБ ЕГО ИЗГОТОВЛЕНИЯ

Группа изобретений относится к медицине. Описано медицинское изделие с нанесенным на основу антибактериальным покрытием из твердого материала с биоцидом. Это покрытие из твердого материала включает в себя по меньшей мере один внутренний слой и один наружный слой, при этом концентрация биоцида в наружном слое по существу постоянна и больше, чем концентрация биоцида во внутреннем слое, и концентрация биоцида во внутреннем слое больше или равна 0,2 ат.%. Покрытие обладает улучшенной адгезией к подложке. 2 н. и 7 з.п. ф-лы, 6 ил., 1 пр.

СИСТЕМА ДОСТАВКИ ЛЕКАРСТВЕННОГО ВЕЩЕСТВА И СПОСОБ ЕЕ ИЗГОТОВЛЕНИЯ

Группа изобретений относится к области доставки лекарственных веществ. Система доставки лекарственного вещества содержит: медицинское устройство с поверхностной областью, а также слой лекарственного вещества, образованный на поверхностной области. При этом слой лекарственного вещества состоит из осажденного лекарственного вещества на поверхностной области и карбонизированного или уплотненного слоя, образованного из осажденного лекарственного вещества путем облучения наружной поверхности осажденного лекарственного вещества. При этом карбонизированный или уплотненный слой не проникает сквозь осажденное лекарственное вещество и выполнен с возможностью высвобождения лекарственного вещества с заданной скоростью. При этом облучение включает в себя облучение пучком ускоренных нейтральных частиц, полученных из пучка ускоренных газовых кластерных ионов. Также раскрывается способ обеспечения системы доставки лекарственного вещества. Группа изобретений обеспечивает усовершенствование механизма высвобождения ...

ОРТОПЕДИЧЕСКИЙ ИМПЛАНТ, ИМЕЮЩИЙ ПОКРЫТИЕ ИЗ КРИСТАЛЛИЧЕСКОГО ГИДРОКСИАПАТИТА, СОДЕРЖАЩЕГО ГАЛЛИЙ, И СПОСОБЫ ЕГО ИЗГОТОВЛЕНИЯ

Изобретение относится к ортопедическому имплантату. Ортопедический имплантат содержит металлическую поверхность и слой гидроксиапатита, нанесенный на по меньшей мере часть металлической поверхности. Слой гидроксиапатита содержит ионы галлия и является кристаллическим и при проведении XRD образует пик при угле 2θ 26±2° (002) XRD и пик при угле 2θ 32±2° (112) XRD, и при этом пик (002) XRD имеет интенсивность, которая в 1,5-10 раз превышает интенсивность пика (112) XRD. Технический результат – получение покрытия из фосфатат кальция, которое быстро образуется и имеет микроструктуру, допускающую равномерное разложение в течение периода нескольких недель без образования частиц. 13 з.п. ф-лы, 9 табл., 32 ил., 21 пр.

ВЖИВЛЯЕМОЕ УСТРОЙСТВО

Изобретение относится к медицинской технике, а именно к вживляемому устройству. Вживляемое устройство для использования в теле человека и/или животного с целью закрытия или частичного закрытия отверстий дефектов, полостей, каналов, протоков в органах и т.п. или создания заданного соединительного отверстия между стенками, органами, полостями и т.п. имеет несущую структуру. Первичная форма несущей структуры имеет большее отношение длины к поперечному измерению вдоль оси, а вторичная форма - меньшее отношение длины к поперечному измерению вдоль оси. Несущая структура включает в себя проксимальный участок и дистальный участок и имеет форму плетения и/или ткани и/или холста и/или сетки. По меньшей мере, один участок во вторичной форме содержит две части, одна из которых первой разворачивается из первичной формы во вторичную форму и складывается в направлении от другого участка на вторую часть, направленную к этому другому участку. Сложенная часть складывается обратно вовнутрь вживляемого устройства ...

СПОСОБ НАНЕСЕНИЯ ПОКРЫТИЯ НА МЕДИЦИНСКОЕ УСТРОЙСТВО, ВХОДЯЩЕЕ В КОНТАКТ С ТКАНЯМИ ТЕЛА

Изобретение относится к медицинской технике, а именно к инъекционной игле, входящей в контакт с тканями тела. Инъекционная игла включает покрытие, полученное путем очистки и активации поверхности иглы ускоренными ионами и дальнейшего ионно-плазменного напыления сначала потоком газообразных ускоренных частиц, содержащим кремнийорганическое соединение, и далее ионно-плазменное напыление потоком газообразных ускоренных частиц, содержащим атомы металлов: железа (Fe) и/или титана (Ti). Технический результат – получение покрытия на инъекционной игле, которое позволяет проводить измерения электрических параметров биологической среды (электрический импеданс) в области колющей части иглы по мере введения иглы в биоткани, при этом результат измерения не зависит от скорости введения, что позволяет с высокой точностью контролировать положение иглы в реальном времени. 1 ил.

Бактерицидное покрытие

Изобретение относится к многослойному наноструктурированному бактерицидному покрытию из нитридов титана и гафния. Упомянутое покрытие состоит из слоев нитрида титана и нитрида гафния и содержит следующие химические элементы, мас. %: титан 10-12, гафний 80-81 и азот 7-10. Слои нитрида титана и нитрида гафния выполнены чередующимися, имеют толщину от 6 до 20 нм и расположены параллельно подложке. Верхний слой покрытия состоит из нитрида гафния. Общая толщина указанного покрытия составляет от 3 до 6 мкм. В зоне плоскости контакта слоев нитрида титана и нитрида гафния образована кристаллическая фаза замещения TiHfN2 толщиной менее 2 нм. Обеспечивается бактерицидное покрытие для имплантатов с повышенной твердостью и повышенной коррозионной стойкостью. 1 табл., 6 пр.

Способ покрытия синтетического герниоимплантата для достижения коллагенстимулирующего и противовоспалительного эффекта.

Изобретение относится к медицине, а именно хирургии грыж передней брюшной стенки, и раскрывает способ покрытия синтетического герниоимплантата. Способ характеризуется тем, что включает использование метилцеллюлозы и декспантенола. Способ включает следующие стадии: набухание и растворение полимера метилцеллюлозы, для чего порошок метилцеллюлозы в асептических условиях заливают горячей водой 80-90°С, оставляют на 2 часа, декспантенол растворяют в очищенной воде комнатной температуры, раствор декспантенола добавляют к раствору метилцеллюлозы, перемешивают и оставляют для деаэрации на 5 часов, полученный раствор выливают в чашку Петри и помещают в нее синтетический имплантат для иммобилизации на 1 час, имплантат с покрытием сушат 4-5 часов при температуре 20-25°С на гладкой стеклянной поверхности, помещают в упаковку, стерилизуют. Изобретение позволяет получать коллагенстимулирующий и противовоспалительный эффект покрытия синтетического имплантата на основе декспантенола. 2 пр.

МНОГОБЛОЧНЫЕ УСТРОЙСТВА ДЛЯ ДОСТАВКИ ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ДОСТАВКИ ЛЕКАРСТВЕННОГО СРЕДСТВА

Сверхпрочная ультратонкая коллагеновая мембрана и способ ее получения

Группа изобретений относится к области тканевой инженерии, в частности к коллагеновым мембранам, используемым в качестве ксеноимплантатов и раскрывает коллагеновую мембрану из биоткани кальмара и способ ее получения. Коллагеновая мембрана из биоткани кальмара вида Dosidicus Gigas семейства Ommastrephinae обладает с прочностью на разрыв 150-250 МПа, относительном удлинении при разрыве не менее 20%, толщиной от 20 до 100 мкм, с отклонением по толщине от среднего значения не более 5%, с содержанием коллагена не менее 98% в пересчете на абсолютно сухое вещество. Способ получения включает разделку туши кальмара на отдельные анатомические части механическим способом, с отделением покровной соединительной биоткани мантии, которая последовательно выдерживается в растворе нейтральной соли, в слабощелочном растворе, содержащем липолитический и протеолитический ферменты, после чего промывается водой, раствором кислоты с высокой ионной силой, затем щелочным раствором, дистиллированной водой и высушивается ...

ПОДЛОЖКА С ЭЛЕКТРОНОДОНОРНОЙ ПОВЕРХНОСТЬЮ, СОДЕРЖАЩЕЙ ЧАСТИЦЫ МЕТАЛЛА, ВКЛЮЧАЯ ПАЛЛАДИЙ

... 1. Подложка, имеющая электронодонорную поверхность, отличающаяся тем, что на указанной поверхности находятся металлические частицы, причем указанные металлические частицы содержат палладий и по меньшей мере один металл, выбранный из группы, состоящей из золота, рутения, родия, осмия, иридия и платины, при этом количество указанных металлических частиц составляет примерно от 0,001 до 8 мкг/см2. ! 2. Подложка по п.1, отличающаяся тем, что указанная электронодонорная поверхность представляет собой слой электронодонорного материала, нанесенного в количестве примерно от 0,05 до 12 мкг/см2. ! 3. Подложка по п.2, отличающаяся тем, что указанный электронодонорный слой является металлом, менее благородным, чем любой металл из группы, состоящей из палладия, золота, рутения, родия, осмия, иридия и платины. ! 4. Подложка по п.3, отличающаяся тем, что указанный электронодонорный слой является металлом, выбранным из группы, состоящей из серебра, меди и цинка. ! 5. Подложка по любому из пп.1-4, отличающаяся ...

АНТИМИКРОБНЫЕ КОМПОЗИЦИИ

НОВЫЙ АНАЛОГ ОКСИСТЕРОЛА, OXY149, ИНДУЦИРУЕТ ОСТЕОГЕНЕЗ И СИГНАЛЬНЫЙ ПУТЬ HEDGEHOG И ИНГИБИРУЕТ ЛИПОГЕНЕЗ

... 1. Соединение Oxy149, имеющее формулу Iили его фармацевтически приемлемая соль или сольват.2. Биоактивная композиция, содержащая соединение Oxy149 и фармацевтически приемлемый носитель.3. Биоактивная композиция по п. 2, дополнительно содержащая, по меньшей мере, одно добавочное средство, выбранное из группы, состоящей из паратиреоидного гормона, фторида натрия, инсулиноподобного фактора роста I (ILGF-I), инсулиноподобного фактора роста II (ILGF-II), трансформирующего ростового фактора бета (TGF-β), ингибитора цитохрома Р450, остеогенного простаноида, BMP 2, BMP 4, BMP 7, BMP 14 и/или противорезорбтивного средства.4. Способ лечения субъекта, имеющего заболевание кости, остеопороз или перелом кости, включающий введение субъекту эффективного количества биоактивной композиции по п. 2.5. Способ по п. 4, включающий введение субъекту биоактивной композиции в терапевтически эффективной дозе в эффективной лекарственной форме с подобранным интервалом с целью увеличения костной массы.6. Способ по ...

Implant, preferably brain pacemaker useful for treating Parkinson's disease, comprises an implant base body, anchor groups on the surface of the implant base body, and aptamers, which are bonded to the anchor groups

Implant comprises (a) an implant base body; (b) one or more anchor groups on the surface of the implant base body; and (c) one or more aptamers, which are bonded to the anchor groups, where: the anchor group is a phosphorus containing group (I) or its salt or hydrate, the aptamer is aligned in such a manner that it binds with: one or more physiological components of a human or animal organism and/or one or more systemically administered active agent under physiological conditions of a human or animal organism. Implant comprises (a) an implant base body; (b) one or more anchor groups on the surface of the implant base body; and (c) one or more aptamers, which are bonded to the anchor groups, where: the anchor group is a phosphorus containing group of formula ((R 2>O) 2-(O)-P-L-(CH 2) x-M-R 1>) (I) or its salt or hydrate, the aptamer is aligned in such a manner that it binds with: one or more physiological components of a human or animal organism and/or one or more systemically administered ...

SCHÜTZENDE KÄFIGSTRUKTUR ZUR BESCHICHTUNG VON MEDIZINISCHEN GERÄTEN

Coated implant, e.g. coronary stent or artificial joint or bone, adapted for release of and in situ reloading with active agent via inter-active binding partners

Coated implant has at least one pair of binding partners of which at least one partner is fixed to the implant and at least one partner is non-fixed. The partners inter-react non-covalently to facilitate the constant, continuous and complete release of the non-fixed binding partner in the environment of the implant when fully loaded on the surface of the implant.

HERSTELLUNG BESCHICHTETER MEDIZINISCHER GERÄTE MITTELS LASERABLATION

A magnetic field controllable implantable device and a method of controlled drug release therefrom

Novel process and products

A method of producing an anti-coagulant surface, said method comprising exposing the surface to a plasma comprising a monomer or a sequence of monomers, wherein the monomer or sequence of monomers are capable of forming an anti-coagulant polymer or a precursor thereof, and wherein at least one of said monomers contains an oxygen or nitrogen containing functional group, controlling the plasma conditions so that a layer of anti­coagulant polymer or a precursor thereof is deposited on the surface, and then if necessary, converting any precursor of anti-coagulant polymer to anti-coagulant polymer. Also claimed is a method of producing an anti-coagulant surface wherein at least one of said monomers contains an oxygen or nitrogen containing functional group. Substrates obtainable using this method are also claimed, such as blood-bags, syringes, syringe needles, stents, implants or tubing components. Preferably a precursor of an anti-coagulant polymer with multiple hydroxyl groups on proximal ...

Functionalised coated medical device and method of coating such a device

Bio-compatible polymeric materials

Coated medical device and method of coating such a device

Functionalising at least one surface 50 of a structure 14 by acidification or basification by polar acid or base and applying a coating 54 to the functionalised surface 52, the coating 54 comprising a conjugate acid or base of the acid or base used in functionalising. Functionalization may be by a carboxylic acid which may be citric, acetic, lactic, ascorbic or tannic acid or by the conjugate bases thereof. The coating 54 is preferably bioactive and may include a therapeutic substance, preferably the coating 54 includes an anti-proliferactive substance and most preferably includes paclitaxel. The coating 54 may be free of containment elements, binding agents and matrix materials such as polymers and may include dispersal facilitators and/or an excipient. Preferably the entirety of the at least one surface 50 is functionalised and this step does not remove oxides present. The method may include steps of atomically cleaning, preferably with plasma, and/or alcohol cleaning, which may use ethanol ...

Coated Implantable Medical Devices

Coated implantable medical devices where the surface can be both hydrophobic and oleophobic. Device such as catheter, vascular graft, cardiac pacer lead, heart diaphragm suture, needle, angioplasty device, artificial joint heart valve, neurological stimulators or drug pump, stents with biofilm, sirolimus-eluting stent, paclitaxel-eluting stent and device reducing thrombosis. Repellent coating such as calixarenes and resorcarene can be used.

Methods and processes for application of drug delivery polymeric coatings

USE FROM CYTOSKELETTINHIBITOREN TO THE PREVENTION THE RESTENOSE

Condom with Warmth Imparting Lubricant

A condom together with a lubrication composition, the lubricating composition containing a minimal amount of free water, and comprising one or more glycols, such that the glycols in the lubricant release heat and warmth when contact with compositions containing free water.

Implant and method for producing the same

An implant and method for producing an implant, in particular an intraluminal endoprosthesis, with a body, wherein the body contains iron or an iron alloy, comprising the following steps: a) providing the implant body ( 1 ), b) applying a metallic coating comprising as main constituent at least one element of the group containing tantalum, niobium, zirconium, aluminum, magnesium, vanadium, molybdenum, hafnium, and wolfram onto at least a portion of the body surface, and c) plasmachemical treatment of the portion of the body surface provided with the coating in an aqueous solution for producing a plasmachemically generated layer ( 3, 5, 7 ) by means of applying a plasma-generating pulsating voltage to the body of the implant, wherein the pulsating voltage has sufficient energy that the metallic coating ( 3, 5, 7 ) is temporarily and sectionally ionized up to the underlying implant body ( 1 ) in such a manner that the generated layer has pores ( 5 ) which extend at least partially up to the implant body.

Coated medical devices and methods

The invention relates to medical device systems that include a delivery instrument comprising a sheath having an abluminal surface and a luminal surface; a radially-expandable frame disposed at least partially within the sheath, the frame having an abluminal surface at least partially in contact with the luminal surface of the sheath, and a luminal surface defining a sub-stantially cylindrical lumen; and a fine powder coating disposed on at least one of the abluminal surface of the frame and the luminal surface of the sheath. The invention also relates to methods of manufacturing, loading, and delivering the coated medical devices.

Enhancing biocompatibility of a medical device

The present invention relates to a medical device comprising both pyrolytic carbon and an NO generator, methods of making same, and methods of using same.

Methods Of Drug Loading A Hollow Stent With A High Viscosity Formulation

A method of loading a composition into a structural element of a stent, where the structural element is defined by a lumen and at least one opening to access the lumen. The composition may include a therapeutic agent. In some embodiments, the composition has characteristics such that at a temperature of 20° C. to 30° C. and a pressure of one atmosphere, the viscosity of the composition is about 10 cP or greater than 10 cP.

Method for Making Medical Devices Having Antimicrobial Coatings Thereon

The present invention provides a method for preparing a medical device, preferably a contact lens, having an antimicrobial metal-containing LbL coating on a medical device, wherein the antimicrobial metal-containing LbL coating comprises at least one layer of a negatively charged polyionic material having —COOAg groups and/or silver nanoparticles formed by reducing Ag + ions associated with the —COO − groups of the negatively charged polyionic material. In addition, the present invention provides a medical device prepared according to a method of the invention.

Polymer-Based Occlusion Devices, Systems and Methods

A method of occluding includes imbibing a porous elongate element comprised of ePTFE with a calcium-containing solution. The method also includes delivering, via a delivery catheter, the calcium-imbibed porous elongate element to a target occlusion site. The method further includes administering, after the calcium-imbibed porous elongate element has been completely delivered to the target occlusion site and resides entirely within a volume defined by the target occlusion site, an alginate-containing solution to the target occlusion site.

ISOLATION OF MESENCHYMAL STEM CELLS

The present invention relates to peptides or fragments thereof, which peptides bind to mesenchymal stem cells. The present invention also relates to a method for identifying, isolating, specifically selecting and/or enriching mesenchymal stem cells, wherein the peptides, or fragments thereof, are employed for specifically binding to the mesenchymal stem cells. Also, the present invention relates to the use of the peptides of the invention, or fragments thereof, and of the mesenchymal stem cells isolated with the peptides of the invention, or fragments thereof, for treating, injuries and/or degenerated bone, cartilage or tissues. 1. A method for selecting and/or enriching mesenchymal stem cells (MSCs) from a sample , comprising the steps ofcontacting a sample containing mesenchymal stem cells and other cell types with a peptide, or a fragment thereof, wherein the peptide or fragment thereof specifically binds to mesenchymal stem cells, and wherein the peptide is selected from the group consisting of laminin-1, collagen-1, collagen-3, collagen-4, tenascin, thrombospondin-1, osteopontin, fibronectin, vitronectin, and mixtures thereof, thereby allowing binding of the peptide or fragment thereof to mesenchymal stem cells,selecting and/or enriching the mesenchymal stem cells bound to the peptide or fragment thereof from the other cell types not bound to the peptide or fragment thereof.2. The method as claimed in claim 1 , wherein the peptide fragment is:a) a peptide consisting of the amino acid sequence set forth as one of SEQ ID NOs: 8 to 32;b) fragments of the sequences according to a), which have a substantially identical biological activity of the peptide according to a) in an assay relating to the binding of mesenchymal stem cells; orc) a peptide fragment with a sequence that is at least 80% identical one of the sequences stated in a) and b).3. The method as claimed in claim 1 , wherein the sample is from a primary culture or a previously cultured cell population.4. ...

Anti-microbial metal organic framework

The present invention relates to metal organic framework materials which possess anti-microbial properties. The present invention also provides methods of preparing such metal organic framework materials and uses of the metal organic framework materials to prevent or treat microbial infections, or provide surfaces which limit contamination by micro-organisms.

Modified surface for an implantable device and a method of producing the same

Implantable devices, such as stents, having a surface modified with TiN x C y are disclosed.

MEDICAL DEVICE WITH COATING THAT PROMOTES ENDOTHELIAL CELL ADHERENCE AND DIFFERENTIATION

Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed. 1. An implantable medical device comprising a multiple layer coating matrix attached to at least a portion of said medical device , wherein said matrix promotes the capture and growth of endothelial cells or endothelial progenitor in vivo.2. The implantable medical device of claim 1 , wherein the medical device is selected from the group consisting of a stent claim 1 , a stent graft claim 1 , a synthetic vascular graft claim 1 , a heart valve claim 1 , a catheter claim 1 , a vascular prosthetic filter claim 1 , a pacemaker claim 1 , a pacemaker lead claim 1 , a defibrillator claim 1 , a patent foramen oval septal closure device claim 1 , a vascular clip claim 1 , a vascular aneurysm occluder claim 1 , a hemodialysis graft claim 1 , a hemodialysis catheter claim 1 , an atrioventricular shunt claim 1 , an aortic aneurysm graft device claim 1 , a venous valve claim 1 , a suture claim 1 , a vascular anastomosis clip claim 1 , an indwelling venous catheter claim 1 , an indwelling arterial catheter claim 1 , a vascular sheath and a drug delivery port.3. The implantable medical device of claim 1 , wherein the ...

Stent Coating Apparatus with Fibers

A stent coating apparatus for coating a stent includes a brush assembly, a stent support, and a dispensing mechanism. The brush assembly includes a plurality of fibers, and the stent support carries a stent at a position in which the stent is in contact with the fibers. The dispensing mechanism dispenses a coating composition to the plurality of fibers.

IMPLANTABLE MEDICAL DEVICE WITH BENEFICIAL AGENT CONCENTRATION GRADIENT

The implantable medical devices are configured to release at least one therapeutic agent from a matrix affixed to the implantable body with a release profile which is programmable to the agent and treatment. The matrix is formed such that the concentration of the therapeutic agent in the matrix varies as a gradient relative to a surface of the implantable body. The change in the concentration gradient of the agent in the matrix directly controls the rate of elution of the agent from the matrix. The therapeutic agent matrix can be disposed in the stent or on surfaces of the stent in various configurations, including within volumes defined by the stent, such as openings, holes, or concave surfaces, as a reservoir of agent, and alternatively as a coating on all or a portion of the surfaces of the stent structure. 1. A method of forming an implantable medical device configured to release at least one therapeutic agent therefrom , the method comprising:providing an implantable medical device having a body, a luminal surface, a mural surface and at least one recess in the body;forming a first homogeneous solution comprising the at least one therapeutic agent mixed with a polymeric binder;introducing the first homogeneous solution into the at least one recess in the body of the implantable medical device;solidifying the first homogeneous solution, thereby forming a first portion of a matrix, wherein a concentration of the at least one therapeutic agent in the matrix varies as a continuous gradient relative to a surface of the body of the implantable medical device;forming a second homogeneous solution comprising the polymeric binder;applying the second homogeneous solution to the first portion of the matrix, thereby at least partially liquifying the first portion of the matrix; andsolidifying the second homogeneous solution, thereby forming a second portion of the matrix, wherein the concentration of the at least one therapeutic agent in the matrix is higher at the luminal ...

Implant with a base body of a biocorrodible alloy

An implant having a base body, comprised either entirely or in part of a biocorrodible metallic material wherein at least the parts of the base body having the biocorrodible metallic material are at least partially covered with a coating of a crosslinked CF x layer that is nonpolymerized and has an F/C ratio in the range of 0.5 to 1.5.

Coating suitable for surgical instruments

A coating and devices using the coating are provided. The coating is applied in liquid form and dried or otherwise cured to form a durable adherent coating resistant to high temperatures and having optional hydrophobic properties. The coating formulation contains an aqueous formulation of silica, one or more fillers, and sufficient base, (e.g., potassium hydroxide), to have a pH exceeding about 10.5 during at least part of the formulation process. The formulation may contain a compound(s) that affects surface free energy, energy to make the cured coating hydrophobic. Such compounds include silanes containing halogens (e.g., fluorine or chlorine) and in particular silanes containing one or more hydrolyzable groups attached to at least one silicon atom and a group containing one or more halogens (e.g., chlorine or fluorine). A medical instrument (e.g., electrosurgical instrument) may be at least partially covered by a coating using the formulation.

MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE

The present disclosure provides a device for intracorporeal use which comprises an implant or a temporary device and at least one source of myolimus or a derivative thereof. The present disclosure also provides a method of inhibiting cell proliferation, inflammation or cytokine production by systemic or local administration of a therapeutically effective amount of myolimus or a derivative thereof. Further included in the present disclosure is a method of treating an ophthalmic condition or disease by administering a therapeutically effective amount of myolimus or a derivative thereof. 2. The medical device of claim 1 , wherein the medical device is configured to release the macrocyclic lactone to a lumen or organ of a mammalian body to inhibit cell proliferation claim 1 , inflammation or cytokine production.3. The medical device of claim 2 , wherein the medical device is configured to release the macrocyclic lactone to a lumen or organ of a mammalian body to inhibit smooth muscle cell proliferation and inflammation.4. The medical device of claim 1 , wherein the implant is a luminal prosthesis.5. The medical device of claim 4 , wherein the luminal prosthesis comprises an expandable scaffold.6. The medical device of claim 4 , wherein the luminal prosthesis comprises a stent or a graft.7. The medical device of claim 6 , wherein the luminal prosthesis is a vascular stent.8. The medical device of claim 7 , wherein the stent is substantially fully degradable.9. The medical device of claim 7 , wherein the stent is balloon expandable.10. The medical device of claim 4 , wherein the luminal prosthesis has a luminal surface and a tissue-facing surface claim 4 , and wherein the macrocyclic lactone is associated with at least one of the luminal and tissue-facing surfaces.11. The medical device of claim 1 , wherein at least 75% of the macrocyclic lactone is released from the medical device in a period from about 1 day to about 2 years.12. The medical device of claim 1 , wherein ...

MEDICAL DEVICE HAVING A SURFACE COMPRISING ANTIMICROBIAL METAL

A medical device intended for contact with living tissue comprises a substrate having a surface, which surface comprises a layer comprising one or more compound(s)) of at least one non-toxic post-transition metal, such as a gallium or bismuth compound. A layer comprising a compound of a non-toxic post-transition metal has been shown to inhibit biofilm formation on the surface of the medical device, which may reduce the risk for infection e.g. around a dental implant. A method of producing the medical device comprises: a) providing a substrate having a surface; and applying a compound of a non-toxic post-transition metal onto said surface to form a layer, e.g. using a thin film deposition technique. 1. A medical device intended for contact with living tissue , comprising a substrate having a surface layer comprising one or more compound(s) of a non-toxic post-transition metal.2. The medical device according to claim 1 , wherein said living tissue is soft tissue.3. The medical device according to claim 1 , wherein said compound of a non-toxic post-transition metal also comprises an additional metal.4. The medical device according to claim 1 , wherein said surface layer is a metallic layer and said compound of a non-toxic post-transition metal is a metallic compound.5. The medical device according to claim 1 , wherein said non-toxic post-transition metal is selected from bismuth and gallium.6. The medical device according to claim 1 , wherein said compound of a non-toxic post-transition metal is selected from the group consisting of gallium-titanium claim 1 , gallium-titanium oxide claim 1 , gallium-titanium nitride claim 1 , gallium nitride claim 1 , gallium carbide claim 1 , gallium selenide claim 1 , and gallium sulphide claim 1 , gallium chloride claim 1 , gallium fluoride claim 1 , gallium iodide claim 1 , gallium oxalate claim 1 , gallium phosphate claim 1 , gallium maltolate claim 1 , gallium acetate and gallium lactate.7. The medical device according to claim 1 ...

INTRALUMINAL DEVICE WITH A COATING CONTAINING A THERAPEUTIC AGENT

The invention relates to an intraluminal device, in particular an intraluminal prosthesis, shunt, catheter or local drug delivery device. In order to increase the bio-compatibility of this device, it is provided with at least one coating. The coating contains a therapeutic agent which is comprised in a matrix that sticks to the intraluminal device. Instead of being formed by a little bio-compatible polymer, the matrix is formed by a bio-compatible oil or fat, such as cod-liver oil or olive oil. Preferably, the bio-compatible oil or fat further comprises alfa-tocopherol. 1. A medical device coating material , wherein the coating material comprises:a vehicle, wherein the vehicle comprises a synthetic oil or fat which has not been subjected to an aggressive polymerization step, and wherein the vehicle comprises one or more omega-3 fatty acids selected from a group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA); andat least one therapeutic agent.2. The coating material of claim 1 , wherein the coating material is configured to deliver the therapeutic agent to tissue of a patient upon implantation in the patient.3. The coating material of claim 1 , wherein the therapeutic agent is dispersed in the vehicle to form the coating material.4. The coating material of claim 1 , wherein the therapeutic agent is dissolved in the vehicle to form the coating material.5. The coating material of claim 1 , wherein the coating material further comprises alpha-tocopherol.6. The coating material of claim 5 , wherein the alpha-tocopherol is alpha-tocopherol acetate.7. The coating material of claim 5 , wherein the alpha-tocopherol comprises at least 30% by weight to at least 70% by weight of the coating material.8. The coating material claim 1 , wherein the coating material further comprises one or more triglycerides.9. The coating material of claim 1 , wherein the oil or fat is an oil selected from a group consisting of fish oil claim 1 , olive oil claim 1 , linseed ...

Adherent Metal Oxide Coating Forming a High Surface Area Electrode

An implantable electrode and method for manufacturing the electrode wherein the electrode has a strong, adherent surface inert coating on a conductive coating on the electrode surface, which demonstrates an increase in surface area of at least five times when compared to smooth platinum of the same geometry. An iridium oxide coating may be formed on a platinum coating by a physical deposition process, such as sputtering. The process of electroplating the iridium oxide surface coating is accomplished by voltage control processes. A gradient coating of iridium oxide ranging in composition from essentially pure platinum to essentially pure iridium oxide is produced by sputtering. 1. An implantable electrode comprising:a substrate having a basic geometric shape;a conductive coating over the substrate having a surface area greater than five times the basic geometric shape;a surface coating of inert material over the conductive coating.2. The implantable electrode according to claim 1 , wherein the surface coating is comprised of iridium oxide.3. The implantable electrode according to claim 1 , wherein the surface coating is comprised of titanium nitride.4. The implantable electrode according to claim 1 , wherein the conductive coating is comprised of platinum grey.5. The implantable electrode according to claim 1 , wherein the electrode has a charge storage capacity that is greater than 35 mC/cm.6. The implantable electrode according to claim 1 , wherein the surface coating is a sputtered coating.7. The implantable electrode according to claim 1 , wherein the conductive coating is an electroplated coating.8. The implantable electrode according to claim 1 , wherein the conductive coating and surface coating are graded coatings.9. The implantable electrode according to claim 1 , wherein the surface coating is rough increasing the surface area of the surface coating over the surface area of the conductive coating.10. The implantable electrode according to claim 1 , wherein ...

Nitric Oxide Generating Medical Devices

Medical devices having a catalyst capable of catalyzing the generation of nitric oxide in vivo and methods of treating a vascular condition using the devices are provided. 1. A medical device comprising a metal complex comprising a metal and at least one ligand , at least one of the ligands or the at least one ligand being a bipyridine ligand;wherein the metal complex attaches to a surface of the medical device or a coating on the medical device, andwherein the metal complex catalyzes the in-vivo generation of nitric oxide.2. The medical device of claim 1 , wherein in vivo generation of nitric oxide is nitric oxide generation in the blood stream or a tissue adjacent to the medical device.3. The medical device of claim 1 , further comprising a coating for the medical device; wherein the coating comprises the polymer to which the metal complex is attached.4. The medical device of claim 1 , wherein the medical device is a bioabsorbable stent comprising the polymer to which the metal complex is attached.5. The medical device of claim 1 , wherein the metal of the metal complex comprises copper.6. The medical device of claim 1 , wherein the metal complex attaches to a surface of the medical device.7. The medical device of claim 6 , wherein the metal complex attaches to the surface of the device via a spacer or to the polymer of the medical device via a spacer.8. The medical device of claim 7 , wherein the spacer is a short chain alkyl group claim 7 , phenyl group claim 7 , aryl group claim 7 , or poly(ethylene glycol).9. The medical device of claim 1 , wherein the metal complex comprises a metal selected from the group consisting of Cu claim 1 , Co claim 1 , Ni claim 1 , Zn claim 1 , Mn claim 1 , Al claim 1 , or Fe.10. The medical device of claim 1 , wherein the metal complex comprises an ion selected from the group consisting of Cu claim 1 , Co claim 1 , Ni claim 1 , Zn claim 1 , Mn claim 1 , Alor Fe.11. The medical device of claim 1 , further comprising a drug adapted ...

PROGENITOR ENDOTHELIAL CELL CAPTURING WITH A DRUG ELUTING IMPLANTABLE MEDICAL DEVICE

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis. 1. An implantable medical device having a luminal surface and a coating; wherein the coating comprises one or more layers of a non-polymer matrix; one or more pharmaceutical substances , and a ligand attached to said matrix and configured to capture circulating progenitor cells on the luminal surface of said device after implantation of said medical device into a patient.2. The implantable medical device of claim 1 , wherein the medical device is a stent claim 1 , a vascular graft claim 1 , a synthetic graft claim 1 , a heart valve claim 1 , a catheter claim 1 , a vascular prosthetic filter claim 1 , a pacemaker claim 1 , a pacemaker lead claim 1 , a defibrillator claim 1 , a patent foramen ovate (PFO) septal closure device claim 1 , a vascular clip claim 1 , a vascular aneurysm occluder claim 1 , a hemodialysis graft claim 1 , a hemodialysis catheter claim 1 , an atrioventricular shunt claim 1 , an aortic aneurysm graft device or components claim 1 , a venous valve claim 1 , a sensor claim 1 , a suture claim 1 , a vascular anastomosis clip claim 1 , an indwelling venous or arterial catheter claim 1 , a vascular sheath and a drug delivery port.3. The implantable medical device of claim 1 , wherein ...

Inductively heated multi-mode surgical tool

Thermal, Electrosurgical and Mechanical modalities may be combined in a surgical tool. Potentially damaging effects in a first modality may be minimized by using a secondary modality. In one example, thermal hemostasis may thus help electrosurgical applications avoid the adverse tissue effects associated with hemostatic monopolar electrosurgical waveforms while retaining the benefits of using incising waveforms.

Modified Surface For An Implantable Device And A Method Of Producing The Same

Implantable devices, such as stents, having a surface modified with TiN x O y or TiN x C y are disclosed.

Coated antimicrobial articles

Antimicrobial articles that include a fatty acid monoester and an enhancer are described that are effective for killing at least 99.9% of microorganisms on the surface of the article.

Biodegradable implant and fabrication method thereof

The present invention can suitably be used even in a site where hydrogen gas is metabolized slowly, such as the osseous tissue. Provided is a biodegradable implant including a biodegradable magnesium member formed of a magnesium alloy and coating layers that coat the biodegradable magnesium member, thereby reducing the degradation rate thereof in a living organism, wherein a depression to be infiltrated by an osteoblast is formed in a surface of the biodegradable magnesium member.

Medical Devices and Implements with Liquid-Impregnated Surfaces

Described herein are medical devices and medical implements with high lubricity to flesh (or biological fluid) and/or inhibited nucleation on its surface. The device has a surface comprising an impregnating liquid and a plurality of micro-scale and/or nano-scale solid features spaced sufficiently close to stably contain the impregnating liquid therebetween. The impregnating liquid fills spaces between said solid features, the surface stably contains the impregnating liquid between the solid features, and the impregnating liquid is substantially held in place between the plurality of solid features regardless of orientation of the surface.

Selective Coating of an Implantable Medical Device

A coating and a method of coating an implantable medical device, such as a stent, is disclosed. The coating compensates for regions of higher stress and resulting strain due to the geometry of the device. Certain embodiments may include a nonuniform coating on the device in which a strain on the nonuniform coating is less than a strain on a uniform coating when the device is placed under an applied stress during use. Other embodiments may include a coating with a greater resistance to strain on higher strain regions of the device. 111-. (canceled)12. An implantable medical device comprising:a first section and a second section, wherein the first section has higher strain than the second section when the device is placed under an applied stress during use; anda nonuniform coating on the device, wherein a strain on the nonuniform coating is less than a strain on a uniform coating when the device is placed under the applied stress during use.1324-. (canceled)25. The device of claim 12 , wherein the nonuniform coating comprises coating material on the second section and no or substantially no coating material on the first section.26. The device of claim 12 , wherein the nonuniform coating comprises a coating on a smaller fraction of a surface area of the first section than a fraction of a surface area of the second section.27. The device of claim 12 , wherein the nonuniform coating comprises a thicker coating on at least a portion of the second section than on at least a portion of the first section of the device.28. The device of claim 12 , wherein the nonuniform coating comprises a coating on less than an entire surface area of the first section.29. The device of claim 12 , wherein the nonuniform coating comprises a band of coating material around or partially around a latitudinal perimeter of the first section.30. The device of claim 29 , wherein the band of coating material is parallel or substantially parallel to the latitudinal axis of the first section.31. The ...

Anchorage Devices Comprising an Active Pharmaceutical Ingredient

An anchorage device comprising a mesh substrate coupled to an implantable medical device is disclosed, where the mesh substrate has a coating comprising a polymer, and the mesh further comprises at least one active pharmaceutical ingredient. The active pharmaceutical agent is designed to elute from the mesh over time. The mesh substrate can be configured to reduce the mass of the anchorage device such that tissue in-growth and/or scar tissue formation at the treatment site is reduced. In some embodiments, the mesh substrate can be formed with a mesh having a low areal density. In some embodiments, the mesh substrate can include one or more apertures or pores to reduce the mass of the substrate. 1. A device comprising a mesh substrate , said mesh substrate having a coating comprising a polymer and at least one active pharmaceutical ingredient , wherein said device provides a barrier between tissue.2. The device of claim 1 , wherein said active pharmaceutical ingredient is selected from the group consisting of anesthetics claim 1 , antibiotics claim 1 , anti-inflammatory agents claim 1 , procoagulant agents claim 1 , fibrosis-inhibiting agents claim 1 , anti-scarring agents claim 1 , leukotriene inhibitors/antagonists claim 1 , cell growth inhibitors and mixtures thereof.3. The device of claim 1 , wherein said active pharmaceutical ingredient is an antibiotic.4. The device of claim 1 , wherein said antibiotic is selected from the group consisting of rifampin and minocycline and mixtures thereof.5. The device of claim 1 , wherein said polymer is selected from the group consisting of polylactic acid claim 1 , polyglycolic acid claim 1 , poly(L-lactide) claim 1 , poly(D claim 1 ,L-lactide)polyglycolic acid[polyglycolide] claim 1 , poly(L-lactide-co-D claim 1 ,L-lactide) claim 1 , poly(L-lactide-co-glycolide) claim 1 , poly(D claim 1 , L-lactide-co-glycolide) claim 1 , poly(glycolide-co-trimethylene carbonate) claim 1 , poly(D claim 1 ,L-lactide-co-caprolactone) claim 1 , ...

IMPLANTABLE DEVICES COATED WITH INSULIN-MIMETIC AGENT COMPOSITES AND METHODS THEREOF

The present invention discloses vanadium-based insulin-mimetic agent composite coatings, application of these coatings onto implantable devices, and use of the implantable devices for accelerating osseous healing. The invention also encompasses methods of manufacturing implantable devices coated with vanadium-based insulin-mimetic agent composite coatings and the implantable devices so manufactured. The implantable devices have wide applications, including but not limited to treating bone fracture, bone trauma, arthrodesis, and other bone deficit conditions, as well as bone injuries incurred in military and sports activities. 1. An implantable device coated by a composite surface coating , said coating comprising an insulin-mimetic agent.2. The implantable device of claim 1 , wherein the insulin-mimetic agent comprises an insulin-mimetic vanadium compound.3. The implantable device of claim 1 , wherein the insulin-mimetic agent comprises an organovanadium compound having a structure of formula VOLor VO(OR)L claim 1 , wherein L is a bidentate monoprotic ligand claim 1 , and R is an organic group.4. The implantable device of claim 3 , wherein L is a bidentate monoprotic ligand selected from hydroxamates claim 3 , 2 claim 3 ,4-diones claim 3 , α-hydroxypyrones claim 3 , α-hydroxypyridinones claim 3 , and amino acids; and R is selected from C-Calkyl claim 3 , phenyl claim 3 , benzyl or C-Calkenyl group claim 3 , each optionally substituted by one to three substituents independently selected from hydroxyl claim 3 , C-Calkyl claim 3 , and halogen.5. The implantable device of claim 1 , wherein said insulin-mimetic agent is selected from the group consisting of vanadyl acetylacetonate (VAC) claim 1 , vanadyl sulfate (VS) claim 1 , vanadyl 3-ethylacetylacetonate (VET) claim 1 , bis(maltolato)oxovanadium (BMOV) claim 1 , bis(kojato)oxovanadium(IV) claim 1 , bis(3-oxy-1 claim 1 ,2-dimethyl-4-pyridinonato)-oxovanadium(IV) claim 1 , bis(2-hydroxymethyl-5-oxy-1-methyl-4- ...

METHODS TO INCREASE FRACTURE RESISTANCE OF A DRUG-ELUTING MEDICAL DEVICE

Methods for increasing the fracture resistance of a polymer stent's drug-polymer coating and scaffolding including applying a coating and crimping using techniques that increase the resistance to fracture in the coating layer and scaffolding and scaffolding. 112-. (canceled)13. A method for making a medical device , comprising:providing a scaffold comprising a polymer; and during the crimping the scaffold has an elevated temperature of between 5 to 20 degrees below a glass transition temperature of the polymer, and', 'the scaffold is crimped to a balloon having a deployed diameter that is between 2 to 5 times the second diameter., 'using a crimping device, crimping the scaffold from a first diameter to a second diameter by plastic deformation of the scaffold, the crimping including at least a first and second diameter reduction of the scaffold, wherein'}14. The method of claim 13 , wherein after each diameter reduction there is a relaxation period where the scaffold has a constant diameter within the crimping device in order to relieve internal stresses while the scaffold has the elevated temperature.15. The method of claim 13 , wherein the scaffold has a W-shaped closed cell pattern and a strut displaces above 130 degrees about a hinge element when the scaffold is crimped to the second diameter.16. The method of claim 13 , wherein the scaffold is made from a tube.17. The method of claim 16 , wherein the tube has an outer diameter greater than the deployed diameter.18. The method of claim 13 , wherein the scaffold polymer is PLLA or PLGA.19. The method of claim 13 , wherein the deployed diameter is about 3 times the second diameter.20. The method of claim 13 , wherein the scaffold has a first and second strut forming a closed cell element and the struts are separated by an angle of greater than 100 degrees before crimping and less than 100 degrees after crimping claim 13 , and the second diameter is 40% of the first diameter.21. The method of claim 13 , wherein the ...

Enhanced low friction coating for medical leads and methods of making

An implantable or insertable medical device can include a silicone substrate and a plasma-enhanced chemical vapor deposition coating on the silicone substrate. The coating may include a silicon-containing compound. A method of forming the coating is also provided.

Molecules and methods for inhibition and detection of proteins

The present application belongs to the field of functional peptides and more particularly to the field of controlled protein aggregation. The invention discloses molecules of a peptide structure as defined in the claims and methods of using such molecules for therapeutic applications and for diagnostic uses, as well as in other applications such as in the agbio field and in industrial biotechnology. The molecules can be used for curing and/or stabilizing infections such as bacterial, fungal and viral diseases, but are also useful in non-infectious human and veterinary diseases. The molecules can also be used for the detection of protein biomarkers and for the prognosis and diagnosis of a variety of diseases.

BIOPASSIVATING MEMBRANE STABILIZATION BY MEANS OF NITROCARBOXYLIC ACID-CONTAINING PHOSPHOLIPIDS IN PREPARATIONS AND COATINGS

The present invention relates to nitro-carboxylic acid (s)-containing phospholipids, to be used for coating of medical devices such as stents, catheter balloons, wound pads or surgical suture material and for bio-passivating compositions, such as rinses, waterproofing solutions, coating solutions, cryoprotection solutions, cold preservation media, lyoprotection solutions, contrast media solutions, preservation and reperfusion solutions containing these compounds as well as preparing solutions thereof and coating medical devices as well as their uses. 2. Use according to claim 1 , wherein the medical compositions are bio-passivating compositions claim 1 , rinsing solutions for medical apparatuses claim 1 , rinsing solutions for wounds claim 1 , impregnation solutions for dressing claim 1 , wound and suture materials claim 1 , coating solutions for medical devices claim 1 , cryoprotection solutions claim 1 , cryopreservation media claim 1 , lyoprotection solutions claim 1 , contrast agent solutions claim 1 , preservation and perfusion solutions for cells claim 1 , tissues and organs.3. Use according to claim 1 , wherein at least one of the residues RCOO— and RCOO— claim 1 , represented as a free acid group RCOOH and RCOOH claim 1 , is a nitrated carboxylic acid selected from the following group: Hexanoic acid claim 1 , Octanoic acid claim 1 , decanoic acid claim 1 , dodecanoic acid claim 1 , tetradecanoic acid claim 1 , hexadecanoic acid claim 1 , heptadecanoic acid claim 1 , Octadecanoic acid claim 1 , Eicosanoic acid claim 1 , docosanoic acid claim 1 , tetracosanoic acid claim 1 , cis-9-tetradecenoic acid claim 1 , cis-9-hexadecenoic acid claim 1 , cis-6-Octadecenoic acid claim 1 , cis-9-Octadecenoic acid claim 1 , cis-11-Octadecenoic acid claim 1 , cis-9-Eicosenoic acid claim 1 , cis-11-Eicosenoic acid claim 1 , cis-13-docosenoic acid claim 1 , cis-15-tetracosenoic acid claim 1 , t9-Octadecenoic acid claim 1 , t11-Octadecenoic acid claim 1 , t3-hexadecenoic acid ...

Novel small molecule inhibitors of biofilm formation and the novel use of previously identified compounds for inhibition of biofilm formation and applications for drug therapy and medical device coating

Novel compounds and the novel use a class of previously identified small molecules for the inhibition of biofilm formation. Inhibition of biofilm formation can play a very important role in contributing to pathogenicity. Bacteria in the biofilm state have been shown to be 10-10,000-fold less susceptible to antibiotic treatment. Estimations made by the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) attribute 65% to 80% of human infections as biofilm mediated. Consequently, biofilm formation is often responsible for chronic infections due to bacterial persistence despite antibiotic treatment. 1. A method for inhibiting biofilm formation by an organism on a surface the method comprising contacting the organism or the surface with a compound having a fused heterocyclic ring structure.5. The method of wherein the compound exhibits no bactericidal activity and no mammalian cell cytotoxicity.6. The method of further comprising contacting the organism or the surface with an antibiotic.7. The method of wherein the antibiotic is selected from beta-lactam antibiotics claim 6 , glycopeptides claim 6 , lipopeptides claim 6 , macrolides claim 6 , monobactams claim 6 , nitrofurnas claim 6 , oxazolidonones claim 6 , quinolones claim 6 , sulphonamides claim 6 , tetracyclines and sulfur drugs.8. The method of wherein the surface is a biological tissue.9. The method of wherein the surface is an inorganic surface.10. The method of wherein the surface is the surface of a medical device.14. The composition of further comprising an antibiotic.15. The composition of wherein the antibiotic is selected from beta-lactam antibiotics claim 14 , cephalosporins claim 14 , glycopeptides claim 14 , lipopeptides claim 14 , macrolides claim 14 , monobactams claim 14 , nitrofurnas claim 14 , oxazolidonones claim 14 , quinolones claim 14 , sulphonamides claim 14 , tetracyclines and sulfur drugs. This application claims the benefit of and priority to US provisional ...

BIOABSORBABLE STENT SYSTEM

A bioabsorbable stent system may comprise one or more bioabsorbable stents and one or more restoration agents, wherein the one or more restoration agents are suitable for a targeting position and are coated on the surface of the bioabsorbable stent. A bioabsorbable stent system may comprise one or more bioabsorbable stents and one or more bioabsorbable films, wherein the bioabsorbable films are loaded with restoration agents and/or drugs suitable for a targeting position. 1. A bioabsorbable stent system comprising one or more bioabsorbable stents and one or more restoration agents , wherein the one or more restoration agents are suitable for a targeting position and are coated on the surface of the bioabsorbable stent.2. The bioabsorbable stent system of claim 1 , wherein the one or more bioabsorbable stents are coated with drugs suitable for the targeting position.3. The bioabsorbable stent system of claim 1 , wherein the one or more restoration agents comprise one or more of stem cells and its carrier claim 1 , epithelial cells and its carrier claim 1 , endothelial cells and its carrier claim 1 , cell growth factors and/or amniotic membrane.4. The bioabsorbable stent system of claim 1 , wherein the bioabsorbable stent comprises one or more bioabsorbable materials comprising one or more of magnesium claim 1 , magnesium alloys claim 1 , zinc alloy claim 1 , iron claim 1 , poly(N-acetylglucosamine) (Chitin) claim 1 , Chitosan claim 1 , poly(3-hydroxyvalerate) claim 1 , poly(lactide-co-glycolide) claim 1 , poly(3-hydroxybutyrate) claim 1 , poly(4-hydroxybutyrate) claim 1 , poly(3-hydroxybutyrate-co-3-hydroxyvalerate) claim 1 , polyorthoester claim 1 , polyanhydride claim 1 , poly(glycolic acid) claim 1 , poly(glycolide) claim 1 , poly(L-lactic acid) claim 1 , poly(L-lactide) claim 1 , poly(D claim 1 ,L-lactic acid) claim 1 , poly(D claim 1 ,L-lactide) claim 1 , poly(L-lactide-co-D claim 1 ,L-lactide) claim 1 , poly(caprolactone) claim 1 , poly(L-lactide-co- ...

Intragastric volume-occupying device and method for fabricating same

Intragastric volume-occupying devices and methods for treating obesity are provided. The devices, which are inflated by carbon dioxide, include an aluminum or silicon oxide barrier layer providing carbon dioxide retention and an alkylene vinyl alcohol polymer layer providing structural integrity in vivo.

Drug Composition and Coating

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization. 1. A medical device for delivering a therapeutic agent to a tissue , the device having a solid surfactant-free particulate coating layer applied to a surface of the device , the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent , when formulated in the coating layer , is stable to sterilization.2. A method for preparing a medical device according to claim 1 , which comprises the steps of combining the therapeutic agent and the at least one organic additive in powder form claim 1 , and then applying the powder to the device to form a solid particulate composition and optionally applying a subsequent thermal treatment step. The present invention relates to solid paclitaxel compositions, medical devices with coatings comprising solid paclitaxel compositions and to ...

Functional film

A functional film that is applied to a surface of a medical apparatus or a biomaterial includes a film of Ti-doped tetrahedral amorphous carbon (ta-C:Ti film).

BIOABSORBABLE STENT

Provided is a biodegradable stent comprising a magnesium alloy free of a rare earth element and aluminum. The stent comprises: a core structure comprising a magnesium alloy containing 90 wt % or more of magnesium as a main component, and zinc, zirconium, and manganese as accessary components, the magnesium alloy being free of a rare earth element and aluminum; a first corrosion resistant layer formed on the core structure and containing magnesium fluoride as a main component; and a second corrosion resistant layer formed on the first corrosion resistant layer and comprising a parylene. A method for producing such a bioabsorbable stent is also provided. 1. A bioabsorbable stent comprising:a core structure comprising a magnesium alloy containing 90 wt % or more of magnesium as a main component, and zinc, zirconium, and manganese as accessary components, the magnesium alloy being free of a rare earth element and aluminum;a first corrosion resistant layer formed on the core structure of the magnesium alloy and containing magnesium fluoride as a main component; anda second corrosion resistant layer formed on the first corrosion resistant layer and comprising a parylene.2. The bioabsorbable stent according to claim 1 , wherein the rare earth element is at least one selected from the group consisting of Sc claim 1 , Y claim 1 , Dy claim 1 , Sm claim 1 , Ce claim 1 , Gd claim 1 , La claim 1 , and Nd.3. The bioabsorbable stent according to claim 1 , wherein in the magnesium alloy claim 1 , unavoidable impurities selected from the group consisting of Fe claim 1 , Ni claim 1 , Co claim 1 , and Cu are contained in a total content of 30 ppm or less.4. The bioabsorbable stent according to claim 3 , wherein the magnesium alloy comprises 0.95 to 2.00 wt % of zinc claim 3 , 0.05 to 0.80 wt % of zirconium claim 3 , 0.05 to 0.40 wt % of manganese claim 3 , and the balance consisting of magnesium and unavoidable impurities.5. The bioabsorbable stent according to claim 1 , wherein the ...

Implantable Device Having an Outer Surface Comprising Gold and Its Use as an Anti-Migration Device

An implantable device comprising a core portion and a capsule encapsulating the core portion, said capsule having an outer surface, wherein at least a portion of the outer surface comprises gold. 1. An implantable device comprising a core portion and a capsule encapsulating the core portion , said capsule having an outer surface , wherein at least a portion of the outer surface comprises gold having a purity greater than 99.00% w/w , preferably 99.99% w/w.2. The implantable device according to claim 1 , wherein the gold is provided as a coating substantially covering the whole outer surface of the capsule.3. The implantable device according claim 1 , wherein the coating is provided as a patchy layer claim 1 , continuous layer claim 1 , wire and/or dots of predetermined sizes of pure gold.4. The implantable device according to claim 1 , wherein the capsule is a solid shell.5. The implantable device according to claim 5 , wherein the implantable device is an encapsulated microchip and the core portion comprises electrical components.6. The implantable device according to claim 1 , wherein the thickness of the coating can be uniformly or heterogeneously distributed across the outer surface of the capsule in the range from 10 0 nm to 4 μm claim 1 , preferably from 50 nm to 3 μm claim 1 , from 60 nm to 2 μm claim 1 , from 70 nm to 1 μm claim 1 , from 100 nm to 1 μm claim 1 , from 200 nm to 800 nm claim 1 , or from 300 nm to 500 nm.7. The implantable device according to for use as an anti-migrating device.8. The implantable device according to claim 7 , wherein the device is for use in the prevention of adverse effects associated with migrating implanted foreign bodies.9. A method for producing an implantable device claim 7 , comprising the steps of:a) providing an implantable device comprising a core portion, and a capsule encapsulating the core portionb) applying gold having a purity greater than 99.00% w/w, preferably 99.99% w/w on at least a part of the outer surface ...

BIOFILM RESISTANT MEDICAL IMPLANT

A method of incorporating silver and/or copper into a biomedical implant includes: providing an implant having an outer surface; depositing silver and/or copper onto the outer surface of the implant; diffusing the silver and/or copper into a subsurface zone adjacent the outer surface; and oxidizing or anodizing the implant after the diffusion step to form an oxidized or anodized layer that contains at least some amount of elemental silver, elemental copper or silver or copper ions or compounds. 1. A method of incorporating silver , copper or both silver and copper into a metallic biomedical implant , comprising:providing an implant comprising a biomedical metal or a biomedical alloy having an outer surface;depositing silver, copper or both silver and copper onto the outer surface;diffusing silver, copper or both silver and copper into the biomedical metal or biomedical alloy beneath the outer surface by heating the implant; andoxidizing or anodizing the outer surface after said diffusing to form an oxidized or anodized layer.2. The method of claim 1 , wherein the oxidized or anodized layer contains at least some amount of elemental silver claim 1 , silver oxide or silver compounds.3. The method of claim 1 , further including claim 1 , before said depositing claim 1 , roughening the outer surface.4. The method of claim 3 , wherein the surface claim 3 , after said roughening and before said depositing claim 3 , has a roughness of from about 0.1 micron to about 10 micron Ra.5. The method of wherein said roughening comprises a physical roughening treatment claim 3 , a chemical treatment that includes soaking the substrate in an alkaline solution for a period of time of about 1 hour to about 24 hours claim 3 , or both the physical roughening and the chemical treatment.6. The method of claim 1 , further comprising claim 1 , before said depositing claim 1 , etching the outer surface using a fluoride solution.7. The method of claim 1 , wherein said diffusing is conducted in ...

BIOCOMPATIBLE IMPLANT

The present invention relates to a biocompatible implant comprising one or more metal(s), metal alloy(s), metal oxide(s) or a combination thereof, wherein a compound selected from the group consisting of an IP, an ester of an IP, and/or a pharmaceutically acceptable salt thereof, or a combination thereof, is/are covalently bound to at least a part of a metal, metal alloy or metal oxide surface of said biocompatible implant. The covalent bond between the IP and the metal, metal alloy or metal oxide surface can be further assisted by the use of a linker. An implant according to the invention provides for a modulated and/or improved osseointegrative effect when implanted into a body, such as a mammalian body, by virtue of the coating comprising covalently bound phytate. 1. A biocompatible implant comprising one or more metal(s) , metal alloy(s) , metal oxide(s) or a combination thereof , wherein a compound selected from the group consisting of an inositol phosphate (IP) , an ester of an IP , a pharmaceutically acceptable salt thereof or a combination thereof , is/are covalently bound , with or without linker , to at least a part of a metal , metal alloy or metal oxide surface of said biocompatible implant.2. A biocompatible implant according to claim 1 , wherein the IP comprises 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 claim 1 , 5 or 6 phosphate groups.31. A biocompatible implant according to clam claim 1 , wherein a linker is bound to said metal claim 1 , metal alloy or metal oxide surface and to said IP claim 1 , ester of an IP claim 1 , a pharmaceutically acceptable salt thereof or a combination thereof.4. A biocompatible implant according to claim 3 , wherein said linker is selected from the group consisting of anhydrides claim 3 , alcohols claim 3 , acids claim 3 , amines claim 3 , epoxies claim 3 , isocyanates claim 3 , silanes claim 3 , halogenated groups claim 3 , and polymerizable groups.5. A biocompatible implant according to claim 1 , wherein said metal(s) ...

Implant for non-luminal area

A bioabsorbable implant for non-luminal region comprising: a core structure including a magnesium alloy having a predetermined shape; a first corrosion-resistant layer containing a magnesium fluoride layer as a main component formed on the core structure via fluorination of a surface of the magnesium alloy; and a second corrosion-resistant layer containing a parylene formed on the magnesium fluoride layer.

POLYMER COATING WITH ANTIMICROBIAL MATERIALS AND METHODS FOR PRODUCING

A method for producing an antimicrobial coating on a surface. The method includes mixing a parylene dimer and an antimicrobial agent to form a mixture, heating the mixture to sublimate the parylene dimer and suspend the antimicrobial agent within the sublimated parylene dimer, pyrolyzing the sublimated parylene dimer to form a parylene monomer while the antimicrobial agent is suspended within the parylene monomer, and condensing the parylene monomer and the antimicrobial agent together on the surface to polymerize the parylene monomer and form a coating containing a parylene polymer and the antimicrobial agent. 1. A method for producing an antimicrobial coating on a surface , the method comprising:mixing a parylene dimer and an antimicrobial agent to form a mixture;heating the mixture to sublimate the parylene dimer and suspend the antimicrobial agent within the sublimated parylene dimer;pyrolyzing the sublimated parylene dimer to form a parylene monomer, the antimicrobial agent suspended within the parylene monomer; andcondensing the parylene monomer and the antimicrobial agent together on the surface to polymerize the parylene monomer and form a coating containing a parylene polymer and the antimicrobial agent.2. The method of claim 1 , further including treating the coating with an oxygen-containing plasma.3. The method of claim 1 , wherein the parylene dimer is selected from the group consisting of [2 claim 1 ,2]-paracyclophane claim 1 , dichloro-[2 claim 1 ,2]-paracyclophane claim 1 , tetrachloro-[2 claim 1 ,2]-paracyclophane claim 1 , and octafluoro-[2 claim 1 ,2]-paracyclophane.4. The method of claim 1 , wherein the antimicrobial agent is present in the mixture in an amount from about 0.0001 wt. % to about 10 wt. %.5. The method of claim 1 , wherein mixing the parylene dimer and the antimicrobial agent includes mixing the parylene dimer and a plurality of antimicrobial nanoparticles claim 1 , the antimicrobial nanoparticles having an average diameter less ...

Resorbable membrane for guided bone regeneration

The invention relates to membranes for guided bone regeneration, comprising a biodegradable polymer that has been treated with a plasma on one of the faces thereof, and on which at least one or more nanometric layers of active oxides has been deposited on one or both of the faces. The invention also relates to uses of and methods for producing said membranes and to implants based thereon.

DRUG COATING LAYER, METHOD OF CONTROLLING MORPHOLOGICAL FORM OF DRUG COATING LAYER, MEDICAL DEVICE, AND METHOD OF DELIVERING DRUG

A drug coating layer which ensures that when a medical device coated with a drug is delivered into a living body, the drug can be prevented from peeling off during delivery operation through a body lumen or cavity such as a blood vessel; and/or a drug coating layer excellent in transferability of a drug to a target tissue; and a method of controlling the morphological form of a drug coating layer are provided. The drug coating layer, which is formed on a substrate surface and contains a water-insoluble drug, has at least one morphological form selected from the group consisting of defined morphological forms (1) to (4) 1. A drug coating layer formed on a substrate surface ,wherein the drug coating layer has at least one water-insoluble drug morphological form selected from the group consisting of the following morphological forms (1) to (4):(1) a first morphological form in which a substantially plate-shaped amorphous phase is predominant at a surface and inside the wholedrug coating layer;(2) a second morphological form in which small incomplete crystals are predominant;(3) a third morphological form in which small incomplete crystals in a network form are present in at least a portion thereof; and(4) a fourth morphological form in which needle- or rod-shaped or spheroidal crystals are present in at least a portion thereof.2. The drug coating layer according to claim 1 ,wherein the drug coating layer has at least one morphological form selected from the group consisting of the first morphological form and the second morphological form, namely,(1) the first morphological form in which a substantially plate-shaped amorphous phase is predominant at a surface and inside the whole drug coating layer, and(2) the second morphological form in which small incomplete crystals are predominant, andthe first morphological form and the second morphological form contain a same drug or different drugs, and the formation of the first morphological form and the second morphological ...

NUCLEATED CELL PRESERVATION BY LYOPHILIZATION

The invention provides freeze-dried nucleated cells, a method for preparing them, and methods of using them for in vitro assays and in vivo therapeutic treatments. The method for preparing the cells includes incubating cells in the presence of a cryoprotective sugar to load them with the sugar, then lyophilizing them without separating the cells from the cryoprotective sugar. In embodiments, the cells are also loaded with one or more bioactive agents. 1. A population of freeze-dried nucleated cells , wherein said population , when rehydrated , has a viability level of at least 20%.2. The population of cells of claim 1 , wherein the population has a viability level of at least 25%.3. The population of cells of claim 1 , wherein the population has a viability level of at least 35%.4. The population of cells of claim 1 , wherein at least some of the cells comprise a bioactive agent.5. The population of cells of claim 4 , wherein the bioactive agent is an antibacterial agent claim 4 , an antiviral agent claim 4 , or an antifungal agent.6. The population of cells of claim 1 , wherein the cells are mammalian cells.7. The population of cells of claim 6 , wherein the cells are human cells.8. The population of cells of claim 6 , wherein the cells are blood cells.9. The population of cells of claim 8 , wherein the cells are B-cells claim 8 , T-cells claim 8 , or stem cells.10. The population of cells of claim 9 , wherein the stem cells are bone marrow stem cells.11. A method for preparing freeze-dried nucleated cells claim 9 , said method comprising:loading nucleated cells with a cryoprotectant in an aqueous environment;contacting the loaded cells with an excipient or bulking agent to create a lyophilization mixture; andlyophilizing the mixture,wherein the method does not include a separation step between loading of the cells and lyophilizing the cells.12. The method of claim 11 , further comprising claim 11 , prior to lyophilizing the mixture claim 11 , contacting the loaded ...

ADHESION ENHANCED CEMENT COATED INTERMEDULLARY NAIL

A medication impregnated bone cement (MIBC) coated intramedullary (IM) nail for fixation of a long bone fracture comprising an IM nail base and medication impregnated bone cement. The bone cement encapsulates at least a portion of the IM nail base and forms an interface between the adjacent surfaces of the IM nail base and the bone cement. The interface between the encapsulating bone cement and the encapsulated IM nail base being enhanced to increase the adhesion of the encapsulating bone cement to the encapsulated IM nail base. The increase in adhesion being sufficient to ensure that the encapsulating bone cement remains adhered to the encapsulated IM nail base when the medication impregnated bone cement coated intramedullary nail is removed from the long bone. 1. A medication impregnated bone cement (MIBC) coated intramedullary (IM) nail for fixation of a long bone fracture comprising:an IM nail base; andmedication impregnated bone cement;wherein said bone cement encapsulates at least a portion of said IM nail base and forms an interface between the adjacent surfaces of said IM nail base and said bone cement;said interface between said encapsulating bone cement and said encapsulated IM nail base being enhanced to increase the adhesion of said encapsulating bone cement to said encapsulated IM nail base;wherein said increase in adhesion is sufficient to ensure that said encapsulating bone cement remains adhered to said encapsulated IM nail base when said medication impregnated bone cement coated intramedullary nail is removed from said long bone.2. The MIBC coated IM nail of claim 1 , wherein said enhancement to increase the adhesion of said encapsulating bone cement to said encapsulated IM nail base is created by a physical enhancement of said interface.3. The MIBC coated IM nail of claim 2 , wherein said physical enhancement of said interface comprises indentations on said surface of said IM nail base adjacent to said bone cement claim 2 , said bone cement filling ...

STENT HAVING FUNCTIONAL MATERIAL COATED ON CELL SPACE THEREOF

The present invention relates to a stent having a functional material coated on a cell space (safe coating space) thereof. The stent of the present invention, as a stent having a space for mounting and coating drugs and other materials for expanding the functions of the stent, is highly feasible as an actual product in consideration of the structure, transfer device, and manufacturing process of the stent as a whole, and secures a coating space (safe coating space) of a functional material in a cell of the stent through quantitative and qualitative modelling. Since an additional increase in volume does not occur even when the stent is press-mounted in a transfer device as a result of mounting a radio marker or a drug in the coating space, the stent of the present invention has excellent radio opacity without obstructing the loading and deployment of the stent, and may stably mount a great amount of a functional drug. 1. A stent having a cell area coated with a functional material.2. The stent of claim 1 , wherein the cell area has a volume defined by equation 1 below:{'br': None, 'i': V', '=A', '×I, 'sub': sa', 'sa', 'scx, 'Equation 1'}{'sub': sa', 'sa', 'scx, 'wherein in equation 1, Vrepresents the average secure coating volume per node and Arepresents the average secure coating area per node, the node meaning a hook or cross; and Irepresents the secure axial length of cell.'}3. The stent of claim 2 , wherein the stent is a wire stent having a cell area comprising a hook claim 2 , a cross claim 2 , or a hook and a cross.5. The stent of claim 2 , wherein the average secure coating area per node (A) is defined by equation 6 below; and wherein in equation 6 claim 2 , Arepresents the maximum secure coating area and is defined by equation 7 below claim 2 , and Nrepresents the total number of nodes per section of stent and is defined by equation 8 below:{'br': None, 'i': A', '=A', '/N, 'sub': sa', 'sx', 't, 'Equation 6'}{'br': None, 'i': A', 'R', '−R', 'A, 'sub': sx', ' ...

ANTIBACTERIAL BIOMEDICAL IMPLANTS AND ASSOCIATED MATERIALS, APPARATUS, AND METHODS

Methods for improving the antibacterial characteristics of biomedical implants and related implants manufactured according to such methods. In some implementations, a biomedical implant comprising a silicon nitride ceramic material may be subjected to a surface roughening treatment so as to increase a surface roughness of at least a portion of the biomedical implant to a roughness profile having an arithmetic average of at least about 500 nm Ra. In some implementations, a coating may be applied to a biomedical implant. Such a coating may comprise a silicon nitride ceramic material, and may be applied instead of, or in addition to, the surface roughening treatment process. 1. A method for improving the antibacterial characteristics of a biomedical implant , the method comprising the steps of:providing a biomedical implant comprising a poly-ether-ether-ketone (PEEK) and/or titanium substrate material; andapplying a coating of a silicon nitride material on the biomedical implant by chemical vapor deposition (CVD), physical vapor deposition (PVD), plasma spraying, electro-deposition, electrophoretic deposition, slurry coating, or high-temperature diffusion, wherein the silicon nitride coating has a thickness of 1 μm to 125 μm.2. The method of claim 1 , wherein the silicon nitride material is selected from α-SiN claim 1 , β-SiN claim 1 , β-SiYAlON claim 1 , and combinations thereof.3. The method of claim 2 , wherein the silicon nitride material is β-SiYAlON.4. The method of claim 1 , wherein the coated biomedical implant has increased bacterial resistance as compared to the substrate material alone.5. The method of claim 1 , wherein the biomedical implant comprises an intervertebral spinal implant.6. The method of claim 1 , wherein the biomedical implant comprises PEEK.7. The method of claim 1 , wherein the biomedical implant comprises PEEK and a SiYAlON coating.8. The method of claim 1 , wherein the biomedical implant comprises titanium.9. The method of claim 1 , ...

Platelet-activated bioadhesive stent coating as an anti-migration mechanism

A stent having an inner surface and an outer surface, the stent comprising a coating composition comprising a platelet-activated adhesive on at least a portion of the outer surface thereof.

INHIBITORY CELL ADHESION SURFACES

Nanostructured surfaces on selected substrates are described which are highly resistant to cell adhesion. Such surfaces on medical implants inhibit fibroblast adhesion particularly on nanorough titanium deposited on smooth silicone surfaces. The nanostructured deposited metal coatings can also be engineered so that several cell types, including endothelial, osteoblast, and fibroblast cells, show little if any tendency to attach to the coated surface in vivo. 1. An implant device comprising:a substrate having a surface; anda nanostructured coating applied to the surface, the coating resulting in a contact angle greater than about 50 degrees, wherein the value of the contact angle is such that cell attachment to the coating is reduced compared to cell attachment to an uncoated surface.2. The implant according to claim 1 , wherein the contact angle is higher for the coated surface than for the uncoated surface.3. The implant according to claim 1 , wherein the uncoated surface results in a contact angle less than 50 degrees.4. The implant device according to claim 1 , wherein the substrate comprises a non-metal.5. The implant according to claim 1 , wherein the coating results in a surface energy value claim 1 , wherein the value of the surface energy is such that cell attachment to the coating is reduced compared to cell attachment to an uncoated surface.6. The implant according to claim 5 , wherein the surface energy value is higher for the coated surface than for the uncoated surface.7. The implant according to claim 1 , wherein the reduction of cell attachment is exhibited by fibroblast claim 1 , endothelial claim 1 , and osteoblast cells.8. The implant according to claim 7 , wherein the fibroblast cell comprises a periodontal ligament fibroblast (PLF) claim 7 , gingival fibroblast (GF) claim 7 , or a mixture of PLF and GF cells.9. The implant according to claim 1 , wherein the cell attachment to the coated surface is an order of magnitude less than cell attachment ...

ZN-GA SERIES ALLOY AND ITS PREPARATION METHOD AND APPLICATION

The invention discloses a Zn—Ga series alloy and a preparation method and application thereof, belonging to the technical field of medical alloys. The Zn—Ga series alloy includes Zn and Ga, and Ga accounts for 0-30 wt % but not including 0. The preparation method is to mix Zn and Ga or Zn, Ga and trace elements, then to obtain a Zn—Ga series alloy by coating paint after smelting or sintering. The mechanical properties of the prepared Zn—Ga series alloy meet the requirements of the strength and toughness of medical implant materials, and it can be degraded in vivo. It has the dual characteristics of biological corrosion degradation and suitable corrosion rate to provide long-term effective mechanical support. 1. A Zn—Ga series alloy is characterized in that it comprises Zn and Ga , and Ga accounts for 0-30 wt % , but not including 0.2. The Zn—Ga series alloy according to is characterized in that the Zn—Ga series alloy further includes trace elements claim 1 , which is at least one of magnesium claim 1 , calcium claim 1 , strontium claim 1 , manganese claim 1 , titanium claim 1 , zirconium claim 1 , germanium claim 1 , copper claim 1 , silicon claim 1 , phosphorus claim 1 , lithium claim 1 , silver claim 1 , tin and rare earth elements.3. The Zn—Ga series alloy according to is characterized in that the trace element accounts for 0-10 wt %.4. The Zn—Ga series alloy according to is characterized in that the surface of the Zn—Ga series alloy is further coated with a degradable polymer coating claim 1 , a degradable ceramic coating or a degradable drug coating.5. The Zn—Ga series alloy according to is characterized in that the preparation material of the degradable polymer coating is at least one of the following 1) and 2):1) any one of polycaprolactone, polylactic acid, polyglycolic acid, L-polylactic acid, polycyanoacrylate, polyanhydride, polyphosphazene, polydioxanone, polyhydroxybutyrate and polyhydroxyvalerates;2) a copolymer of any two or more of polylactic acid, ...

IMPLANTABLE MEDICAL DEVICE

According to the invention there is provided inter alia an implantable medical device with coatings comprising an immobilized heparin moiety and elutable paclitaxel and to methods for making such devices. 1. An implantable medical device with a surface having a coating comprising:a first coating layer comprising an immobilized heparin moiety and a second particulate coating layer comprising elutable paclitaxel and at least one organic additive, wherein at least a portion of the second particulate coating layer is in contact with at least a portion of the first coating layer.2. An implantable medical device according to claim 1 , wherein the medical device is a tubular medical device.3. An implantable medical device according to claim 1 , wherein the first coating layer comprises a polymer.4. An implantable medical device according to claim 3 , wherein the heparin moiety is covalently attached to the polymer.5. An implantable medical device according to or claim 4 , wherein the polymer is a cationic polymer.6. An implantable medical device according to claim 5 , wherein the first coating layer comprises one or more coating bilayers of cationic polymer and anionic polymer claim 5 , the innermost layer being a layer of cationic polymer and the outermost layer being the layer of cationic polymer to which the heparin moiety is covalently attached.7. An implantable medical device according to claim 3 , wherein the heparin moiety is covalently end-point attached to the polymer and wherein the end-point attached heparin moiety is connected through its reducing end.8. (canceled)9. (canceled)10. An implantable medical device according to claim 1 , wherein the or each organic additive is non-polymeric and hydrolytically stable.11. (canceled)12. An implantable medical device according to claim 1 , wherein at least a proportion of the second particulate coating layer comprising paclitaxel and at least one organic additive melts as a single phase at a lower temperature than the ...

METHODS FOR AGGREGATION OF PROTEINS

The present application belongs to the field of functional peptides and more particularly to the field of controlled protein aggregation. The invention discloses molecules of a peptide structure as defined in the claims and methods of using such molecules for therapeutic applications and for diagnostic uses, as well as in other applications such as in the agbio field and in industrial biotechnology. The molecules can be used for curing and/or stabilizing infections such as bacterial,fimgal and viral diseases, but are also useful in non-infectious human and veterinary diseases. The molecules can also be used for the detection of protein biomarkers and for the prognosis and diagnosis of a variety of diseases. 176.-. (canceled)77. A method for down-regulating the biological function of a protein , comprising [{'sub': 0', '1', '1', '2', '1', '3', '2', '4', '2', '1', '2, '(B) Z—X—Y—X—Z—X—Y—X—Z, wherein Zis a linker and Zis selected from a linker or nothing,'}, {'sub': 0', '1', '1', '2', '1', '3', '2', '4', '2', '5', '3', '6', '3', '1', '2', '3, '(C) Z—X—Y—X—Z—X—Y—X—Z—X—Y—X—Z, wherein Zand Zare each independently a linker and Zis selected from a linker or nothing,'}, {'sub': 0', '1', '1', '2', '1', '3', '2', '4', '2', '5', '3', '6', '3', '7', '4', '8', '4', '1', '2', '3', '4, '(D) Z—X—Y—X—Z—X—Y—X—Z—X—Y—X—Z—X—Y—X—Z, wherein Z, Z, and Zare each independently a linker and Zis selected from a linker or nothing,'}, {'sub': 0', '1', '1', '2', '1', '3', '2', '4', '2', '5', '3', '6', '0', '4', '8', '4', '0', '5', '10', '5', '1', '2', '3', '4', '5, '(E) Z—X—Y—X—Z—X—Y—X—Z—X—Y—X—Z—Y-X—Z—X—Y—X—Z, wherein Z, Z, Z, and Zare each independently a linker and Zis selected from a linker or nothing'}], '(a) contacting the protein with a molecule of structure (B), (C), (D), or (E) [{'sub': '0', 'Zis a linker or nothing,'}, {'sub': 1', '2', '3', '4', '5, 'at least one of Y, Y, Y, Y, and Yis identical to, or differs by 1 or 2 amino acid substitutions from, a stretch of contiguous amino acids ...

SURFACE STRUCTURE OF A COMPONENT OF A MEDICAL DEVICE AND A METHOD OF FORMING THE SURFACE STRUCTURE

A method of forming a surface structure of a component of a medical devices includes forming a fatigue-resistant portion, which entails forming a first layer comprising a transition metal selected from the group consisting of Ta, Nb, Mo, V, Mn, Fe, Cr, Co, Ni, Cu, and Si on at least a portion of a surface of the component, where the surface comprises a nickel-titanium alloy, and alloying the transition metal of the first layer with the nickel-titanium alloy of the surface. The method further includes forming a rough outer surface of the fatigue-resistant portion, where the rough outer surface is adapted for adhesion of a material thereto.

COATED PACKAGING

A vessel has an interior surface facing a lumen. The interior surface includes a tie coating or layer, a barrier coating or layer, and a pH protective coating or layer. The tie coating or layer can comprise SiOCor SiNC, where x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3. The barrier coating or layer can comprise SiO, wherein x is from 1.5 to 2.9. The barrier coating or layer reduces the ingress of atmospheric gas into the lumen. The pH protective coating or layer can comprise SiOCor SiNC, as well. In an embodiment, in the presence of a fluid composition contained in the lumen and having a pH between 5 and 9, the calculated shelf life of the package can be more than six months at a storage temperature of 4° C.

NITRITE ELUTING DEVICES AND METHODS OF USE THEREOF

The present disclosure generally relates to implantable devices including a releasable nitrite ion and to methods of preparing and using such compositions and devices. In one embodiment, the device is a stent, for example, a vascular stent. In another embodiment, the nitrite ion is ionically bound to an inorganic ion. 1. A medical device comprising:a base structure having a surface, anda coating on the surface comprising a compound comprising an ionically bonded nitrite ion, wherein the implantable medical device is free of a nitric oxide generator.2. The medical device of claim 1 , wherein the compound is an organic compound.3. The medical device of claim 2 , wherein the organic compound is selected from the group consisting of a secondary amine nitrite claim 2 , dicyclohexylamine nitrite claim 2 , a quarternary ammonium nitrite and tetrabutylammonium nitrite.4. The medical device of claim 1 , wherein the compound is an inorganic compound.5. The medical device of claim 4 , wherein the inorganic compound is selected from the group consisting of nitrous acid claim 4 , ammonium nitrite claim 4 , a metal nitrite claim 4 , sodium nitrite claim 4 , lithium nitrite claim 4 , potassium nitrite claim 4 , calcium nitrite claim 4 , magnesium nitrite claim 4 , nickel nitrite claim 4 , and silver nitrite. .6. The medical device of claim 1 , wherein the coating consists essentially of the compound.7. The medical device of claim 1 , wherein the coating further comprises a polymeric or non-polymeric carrier matrix.8. The medical device of claim 1 , wherein the coating is free of a polymer or non-polymer carrier matrix.9. The medical device of claim 1 , wherein the medical device is selected from the group consisting of a stent claim 1 , a vascular stent claim 1 , a ureteral stent claim 1 , a catheter claim 1 , a balloon claim 1 , a balloon catheter claim 1 , a stent graft claim 1 , a wire guide claim 1 , and a cannula.10. The medical device of claim 9 , wherein the medical device ...

Drug coating layer

Provided are a drug coating layer which has low toxicity and a high intravascular stenosis inhibitory effect, when delivering medical device coated with a drug into the body and medical device using the same. The drug coating layer is a drug coating layer having a morphological form including a plurality of elongated bodies having long axes that each crystal of a water-insoluble drug independently has on a substrate surface, in which the long axes of the elongated bodies are nearly linear in shape, and the long axes of the elongated bodies form an angle in a predetermined range with respect to a substrate plane with which the long axis of the elongated body intersects.

Plasma or cvd pre-treatment for lubricated pharmaceutical package, coating process and apparatus

A syringe comprising a wall having a generally cylindrical interior surface defining a lumen with a primer coating or layer between 1 and 1000 nm thick of SiOx Cy Hz, in which x is from about 0.5 to about 2.4, y is from about 0.6 to about 3, and z is from about 2 to about 9, on at least a portion of the interior surface, the primer coating or layer having an outside surface facing the interior surface of the barrel and an inside surface facing the lumen. A deposit of fluid lubricant on the inside surface of the primer coating or layer is further provided.

METHOD AND DEVICE FOR ENHANCED TRANSDERMAL VISUALIZATION OF MEDICAL DEVICES

Implantable and/or insertable devices having a near-IR fluorescing material that allows the device to be visualized through a patient's skin. Also described herein are apparatuses for imaging devices having a near-IR fluorescing material, and methods of imaging devices having a near-IR fluorescing material from within the body, including methods of modifying an implanted device having near-IR fluorescing material. 1. An arteriovenous shunt (AV shunt) implant device that is configured to be visible through the patient's skin using near-infrared (near-IR) illumination , the device comprising:an elongated tubular body the body comprising polytetrafluoroethylene (PTFE) and having an inner lumen forming an inner layer;a first middle layer extending at least partially over the inner layer, the first middle layer comprising a first substrate and a near-IR dye, wherein the near-IR dye is at a concentration of between 0.0001% to 0.5% w/w and comprises one or more of: 1,1′,3,3,3′,3′-Hexamethylindotricarbocyanine iodide (HITCI), and a rylene dye; anda first outer layer extending over the first middle layer and sealing the first middle layer between the first outer layer and the inner layer.2. The device of claim 1 , wherein the near-IR dye is at a concentration of between 0.001% w/w and 0.1% w/w.3. The device of claim 1 , wherein the tubular body comprises a second middle layer separate from the first middle layer claim 1 , wherein the second middle layer comprises a second substrate and a second near-IR dye.4. The device of claim 3 , wherein the second middle layer is covered by the first outer layer or a second outer layer extending over the second middle layer and sealing the second middle layer between the second outer layer and the inner layer.5. The device of claim 3 , wherein the second near-IR dye is the same as the first near-IR dye and the second substrate is the same as the first substrate.6. The device of claim 1 , wherein the first substrate comprises silicone.7. ...

PROCESSABILITY OF POLYMERIC SUBSTRATES AND RELATED METHODS

The invention described herein consists of a process that enables increased adhesion of thin film materials (such as metals, metal oxides, carbon nanotubes or other materials) to solvent and temperature sensitive, and non-planar, polymer substrates and the fabrication of softening electronics. Importantly, this process can be used to create exceptional embodiments of the disclosed flexible electronic devices having dynamic properties that make them suitable for implantation in the human body. 1. A method for improving the adhesion of films to polymeric materials , the method comprising depositing a first layer of metals , nanotubes or other ionic or electronic conducting materials such as but not limited to iridium oxide , titanium nitride , titanium oxide or graphene oxide , or combinations of the materials onto the surface of a first substrate to prepare a mold; preparing and depositing , solvent casting , or polymerizing a second layer comprised of a polymer on the first layer within the mold; and removing the polymer coated layer from the mold such that the thin film material layer is removed from the first substrate and transferred to the polymer layer which serves as a second substrate.2. The method according to wherein claim 1 , the first layer comprises gold.3. The method according to wherein claim 2 , the first layer further comprises chromium or titanium.4. The method according to wherein claim 1 , the polymer is a (meth)acrylate claim 1 , thiol-ene claim 1 , urea claim 1 , urethane claim 1 , thiourethane claim 1 , ester claim 1 , or olefin with or without an initiator or catalyst.5. The method according to wherein claim 1 , the first layer is patterned prior to the deposition of the second layer.6. The method according to wherein claim 1 , the first substrate is made from the radiation crosslinking of blends of a thermoplastic polymer and a polyunsaturated monomer.7. The method according to wherein claim 1 , the first substrate is formed by curing epoxy.8 ...

COATED MEDICAL DEVICE AND METHOD OF COATING SUCH A DEVICE

A medical device such as a stent () or medical balloon () is at least partially coated with a carboxylic acid layer in order to enhance biocompatibility, reduce thrombogenesis and increase endothelialisation. The coating is preferably of citric acid in non-crosslinked form and preferably non-porous so as to mask the underlying structure of the medical device. The acid coating forms an outer surface of at least a part of the medical device, that is has no other layer or material overlying it, save for in some embodiments a partial coating of a bioactive material. 1. A medical device including:a structure for implantation or disposition inside a patient, the structure including at least one surface;wherein the at least surface is at least partially covered by a layer of a carboxylic acid or a derivative of carboxylic acid;said layer being an outermost layer of the structure.2. A medical device according to claim 1 , wherein the outermost layer is a non-porous layer.3. A medical device according to claim 1 , wherein the outermost layer is at least 90% carboxylic acid or a derivative thereof.4. A medical device according to claim 3 , wherein the outermost layer is carrier free.5. A medical device according to claim 1 , wherein the outermost layer has a thickness of less than 100 nanometres.6. A medical device according to claim 1 , wherein the outermost layer includes in the region of 100 micrograms of carboxylic acid or a derivative thereof.7. A medical device according to claim 1 , wherein the outermost layer is a layer of citric acid.8. A medical device according to claim 1 , wherein the outermost layer is a layer of citric acid mixed with citrate.9. A medical device according to claim 1 , wherein the outermost layer is formed of amorphous carboxylic acid or a derivative thereof.10. A medical device according to claim 1 , wherein the outermost layer is formed of non-crosslinked molecules.11. A medical device according to claim 1 , wherein the outermost layer is ...

Coated medical device and method of coating such a device

A medical device such as a stent (10) or medical balloon (40) is at least partially coated with a saturated carboxylic acid layer in order to enhance biocompatibility, reduce thrombogenesis and increase endothelialisation. The coating is preferably of citric acid in non-crosslinked form and preferably non-porous so as to mask the underlying structure of the medical device. The acid coating forms an outer surface of at least a part of the medical device, that is has no other layer or material overlying it, save for in some embodiments a partial coating of a bioactive material.

Coated Implantable Medical Device and Coating Method

An intracardiac pacing system comprising a fixation element for fixing the intracardiac pacing system to body tissue is disclosed. The fixation element comprises a metallic material, and is at least partially coated with a metal-ion release inhibiting material. Also, a method for coating at least part of an intracardiac pacing system is disclosed. 1. An intracardiac pacing system comprising a fixation element for fixing the intracardiac pacing system to body tissue , wherein the fixation element comprises a metallic material , and wherein the fixation element is at least partially coated with a metal-ion release inhibiting material.2. The system of claim 1 , wherein the fixation element comprises a shape memory alloy.3. The system of claim 2 , wherein the fixation element comprises nitinol.4. The system of claim 1 , wherein the metal-ion release inhibiting material is a Ni-ion release inhibiting material.5. The system of claim 1 , wherein the metal-ion release inhibiting material is an amorphous material.6. The system of claim 1 , wherein the metal-ion release inhibiting material is selected from the group of: a-SiC:H claim 1 , TiN claim 1 , diamond-like carbon claim 1 , and parylene.7. The system of claim 1 , wherein the fixation element comprises one or more tines.8. The system of claim 1 , further comprising a lead extension with a further fixation element for fixing the lead extension to body tissue claim 1 , wherein the further fixation element comprises a metallic material claim 1 , and wherein the further fixation element is at least partially coated with the metal-ion release inhibiting material.9. The system of claim 1 , wherein the metal-ion release inhibiting material has a thickness of 1 nm to 1000 nm.10. A method for coating at least part of an intracardiac pacing system claim 1 , comprising steps of:providing the intracardiac pacing system, wherein the intracardiac pacing system comprises a fixation element for fixing the intracardiac pacing system to ...

Method Of Fabrication Of Implantable Medical Device Comprising Macrocyclic Triene Active Agent And Antioxidant

This invention relates to methods of including an oxygen-sensitive macrocyclic triene on an implantable medical device wherein the device includes separate antioxidant-containing layers above, below or both above and below the drug reservoir layer containing the macrocyclic triene. 1. A method of fabricating an implantable medical device comprising an oxygen-sensitive macrocyclic triene active agent comprising:disposing a drug reservoir layer comprising a therapeutically effective amount of the oxygen-sensitive macrocyclic triene active agent over at least a portion of an implantable medical device body;disposing an antioxidant layer comprising a pharmaceutically acceptable antioxidant over, under or both over and under the drug reservoir layer.2. The method of claim 1 , wherein a barrier layer is disposed between the each antioxidant layer and the drug reservoir layer wherein the barrier layer is substantially impenetrable to the pharmaceutically acceptable antioxidant.3. The method of claim 1 , wherein the pharmaceutically acceptable antioxidant is selected from the group consisting of butylated hydroxytoluene (BHT) claim 1 , butylated hydroxyanisole claim 1 , tert-butyl hydroquinone claim 1 , quinone claim 1 , (C1-C12)alkyl gallate claim 1 , resveratrol claim 1 , an antioxidant thiol claim 1 , cysteine claim 1 , N-acetylcysteine claim 1 , bucillamine claim 1 , glutathione claim 1 , 7-hydroxyethylrutoside claim 1 , carvedilol claim 1 , vitamin C claim 1 , vitamin E claim 1 , α-tocopherol claim 1 , α-tocopherol acetate claim 1 , lycopene claim 1 , a flavanoid claim 1 , carotene and carotenoids.4. The method of claim 3 , where the amount of pharmaceutically acceptable antioxidant in the antioxidant layer(s) is claim 3 , independently in each antioxidant layer claim 3 , about 0.05 percent to about 5.0 percent of the total amount of the macrocyclic triene active agent in the drug reservoir layer.5. The method of claim 3 , wherein the amount of pharmaceutically ...

MRI VISIBLE MEDICAL DEVICE

Cobalt in oxidized state for use as anti-artifact layer () covering a metallic substrate () of a medical device for reducing the production of artifacts in MRI caused by the magnetic property of the metallic substrate (), wherein the anti-artifact layer () is present at outermost surface of the metallic substrate () and has at least 30% of cobalt ratio (at % Co) to the total amount of transition metallic atoms present therein, and at least 90% of cobalt atoms present within the anti-artifact layer () are converted into at least one of Co(II) oxidized state and Co(III) oxidized state. 11212. A medical device comprising a metallic substrate () made of cobalt-based alloy comprising at least one of chromium and iron and having a cobalt-rich composition () which covers as a layer the outermost surface of the metallic substrate () , characterized in that within 10 nm from the external surface of the cobalt-rich composition ():the cobalt-atomic percent is at least 50 at % to the total amount of chromium and iron atoms;being oxidized into at least one of Co(II) and Co(III) oxidized state is at least 90 at % to the total amount of cobalt atoms; and{'sub': 2', '3, 'cobalt atoms being at least one of cobalt monoxide (CoO) and cobalt (II,III) oxide (CoO.CoO) is at least 55 at %, preferably at least 70 at %, to the total amount of cobalt atoms in oxidized state.'}22. The medical device according to claim 1 , wherein claim 1 , within 10 nm from the external surface of the cobalt-rich composition () claim 1 , cobalt atoms being oxidized into at least one of Co(II) and Co(III) oxidized state is at least 95 at % of cobalt atoms claim 1 , preferably all cobalt atoms claim 1 , to the total amount of cobalt atoms.32. The medical device according to or claim 1 , wherein within 10 nm from the external surface of the cobalt-rich composition () claim 1 , the cobalt-atomic percent is at least 60 at % to the total amount of chromium and iron atoms claim 1 , preferably at least 70 at % claim ...

ENDOLUMINAL DEVICE

An endoluminal device includes a device body including a first structure including at least one metal selected from the group consisting of magnesium, zinc, iron and alloys thereof, and a second structure including a least one polymer selected from the group consisting of polylactide, polycaprolactone, poly(trimethylene carbonate), copolymers thereof, and blends thereof. 1. An endoluminal device comprising a device body comprising:a first structure comprising at least one metal selected from the group consisting of magnesium, zinc, iron and alloys thereof, anda second structure comprising a least one polymer selected from the group consisting of polylactide, polycaprolactone, poly(trimethylene carbonate), copolymers thereof, and blends thereof.2. The endoluminal device according to claim 1 , wherein the first structure and/or the second structure comprise at least one filamentary element claim 1 , and the at least one filamentary element is selected from the group consisting of monofilament claim 1 , staple fiber claim 1 , pseudo monofilament claim 1 , multifilament claim 1 , thread claim 1 , yarn claim 1 , wire and combinations thereof.3. The endoluminal device according to claim 1 , wherein the first structure and/or the second structure comprise a textile structure claim 1 , a knitted fabric or braid.4. The endoluminal device according to claim 1 , wherein the first structure comprises magnesium and/or magnesium alloy.5. The endoluminal device according to claim 1 , wherein the second structure comprises at least one of polylactide claim 1 , poly(L-lactide) claim 1 , poly(D claim 1 ,L-lactide) claim 1 , poly(D-lactide) and mixtures thereof.6. The endoluminal device according to claim 1 , wherein the first structure is arranged at a luminal side of the device body.7. The endoluminal device according to claim 1 , wherein the second structure is arranged at an abluminal side of the device body.8. The endoluminal device according to claim 1 , wherein the first ...

HYPOALLERGENIC ORTHOPEDIC SURGICAL INSTRUMENTS AND METHODS

According to an exemplary embodiment, a hypoallergenic orthopedic surgical instrument to prepare bone for the implantation of orthopedic prosthesis may be provided. The instrument may include a hypoallergenic metal alloy such as, but not limited to, titanium nitride, oxidized zirconium, silver, copper, zinc and palladium. In a further embodiment, the hypoallergenic orthopedic surgical may include a high strength, solid low carbon martensitic stainless steel and a thin, high-density hypoallergenic metal alloy coating on the surface of the instrument. According to another exemplary embodiment, a process of building a hypoallergenic orthopedic surgical instrument to prepare bone for the implantation of orthopedic prosthesis may be provided. The process may include cleaning the surface of a high strength, solid low carbon martensitic stainless steel orthopedic surgical instrument to prepare bone for the implantation of orthopedic prosthesis and forming a thin, high-density coating on the surface of the instrument. 1. A hypoallergenic orthopedic surgical instrument to prepare bone for the implantation of orthopedic prosthesis comprising:an orthopedic surgical instrument composed of a hypoallergenic metal alloy.2. The hypoallergenic surgical instrument of claim 1 , wherein the hypoallergenic metal alloy includes metal and at least one of titanium nitride claim 1 , oxidized zirconium claim 1 , silver claim 1 , copper claim 1 , zinc and palladium.3. The hypoallergenic surgical instrument of claim 1 , wherein the hypoallergenic metal is titanium nitride.4. The hypoallergenic surgical instrument of claim 1 , wherein the hypoallergenic metal is zirconium oxide.5. A hypoallergenic orthopedic surgical instrument to prepare bone for the implantation of orthopedic prosthesis comprising:a high strength, solid low carbon martensitic stainless steel; anda thin, high-density coating on the surface of said instrument.6. The hypoallergenic surgical instrument defined in claim 5 , ...

METHODS AND COMPOSITIONS FOR ANTIMICROBIAL TREATMENT

Various embodiments disclosed relate to methods and compositions for antimicrobial treatment. In various embodiments, the present invention provides a method of antimicrobial treatment. The method includes at least one of exposing at least one microbe to a magnetic field, and contacting the at least one microbe with at least one nanoparticle including iron. 1. A method of antimicrobial treatment , the method comprising: exposing at least one microbe to a magnetic field, and', 'contacting the at least one microbe with at least one nanoparticle comprising iron., 'at least one of'}2. The method of claim 1 , wherein the method is a method of treatment of a biofilm claim 1 , wherein the biofilm comprises the at least one microbe.3. The method of claim 1 , wherein the exposing of the microbe to the magnetic field and the contacting of the microbe with the nanoparticle occur at least partially simultaneously.4. The method of claim 1 , wherein the contacting the microbe with the nanoparticle claim 1 , the exposing of the microbe to the magnetic field claim 1 , or the combination thereof claim 1 , is sufficient to kill the microbe.5. The method of claim 1 , wherein the at least one microbe is at least one of a bacteria and a fungus.6. The method of claim 1 , wherein the magnetic field comprises at least one of a static magnetic field claim 1 , a time-varying magnetic field claim 1 , and a magnetic field that oscillates in polarity.7. The method of claim 1 , wherein the exposing of the microbe to the magnetic field comprises exposing the nanoparticle to the magnetic field.8. The method of claim 1 , wherein the nanoparticle is a magnetic nanoparticle.9. The method of claim 1 , wherein the iron in the nanoparticle is part of an iron compound that is at least one of FeO claim 1 , FeO claim 1 , FeO claim 1 , FeO.10. The method of claim 1 , wherein the nanoparticle comprises at least one organic substituent thereon.11. The method of claim 10 , wherein the organic substituent ...

DRUG RELEASING COATINGS FOR MEDICAL DEVICES

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups. 113-. (canceled)14. A medical device for delivering a therapeutic agent to a tissue , the medical device comprising a coating layer overlying an exterior surface of the medical device , the coating layer comprising a therapeutic agent and an additive , wherein:therapeutic agent is chosen from paclitaxel, rapamycin, beta-lapachone, biologically active vitamin D, and combinations thereof;the additive comprises an anionic surfactant chosen from aluminum stearate, sodium stearate, calcium stearate, magnesium stearate, zinc stearate, sodium oleate, zinc oleate, potassium oleate, sodium stearyl fumarate, sodium lauroyl sarcosinate, or sodium myristoyl sarcosinate.15. The medical device of claim 14 , wherein the therapeutic agent is chosen from paclitaxel claim 14 , rapamycin claim 14 , and combinations thereof.16. The medical device of claim 14 , wherein the therapeutic agent comprises paclitaxel.17. The medical device of claim 14 , wherein the additive comprises aluminum stearate claim 14 , sodium stearate claim 14 , calcium stearate claim 14 , magnesium stearate claim 14 , or zinc stearate.18. The medical device of claim 14 , wherein the additive comprises magnesium ...

ANTI-INFECTIVE ANTIMICROBIAL-CONTAINING BIOMATERIALS

A material including a plurality of fatty acid chains cross-linked together and a silver fatty acid salt formed with the fatty acid chains within the material. Methods for forming a material are also included. The silver-containing materials can be utilized alone or in combination with a medical device for the release and local delivery of one or more anti-infective agents. 1. A material comprising:a plurality of fatty acid chains cross-linked together; anda silver fatty acid salt formed with the fatty acid chains within the material.2. The material of claim 1 , wherein the silver fatty acid salt is formed from an interaction between the fatty acid chains and an aqueous silver solution.3. The material of claim 2 , wherein the silver solution includes silver nitrate or silver acetate.4. The material of claim 1 , wherein the fatty acid chains are cross-linked together by at least partially curing an oil.5. The material of claim 1 , wherein the fatty acid chains are omega-3 fatty acids and the oil is a fish oil.6. A coating or film comprising the material of .7. The coating or film of having an additional antimicrobial compound applied to an outer surface of the coating or film.8. A method for forming a material claim 6 , comprising:at least partially curing a fatty acid biomaterial in order to cross-link chains of the fatty acid biomaterial together to form a bioabsorbable gel;soaking the bioabsorbable gel in an aqueous silver solution; andevaporating a solvent from the aqueous silver solution to form silver fatty acid salts within the bioabsorbable gel.9. The method of claim 8 , wherein the aqueous silver solution includes silver acetate or silver nitrate.10. The method of claim 8 , wherein the at least partially curing includes at least partially curing the fatty acid biomaterial onto a medical device.11. The method of claim 11 , wherein the medical device is a bandage claim 11 , a stent claim 11 , a graft claim 11 , a shunt claim 11 , a catheter claim 11 , a ...

DRUG DELIVERY SYSTEM AND METHOD OF MANUFACTURING THEREOF

An apparatus and method provides a drug layer formed on a surface region of a medical device, the drug layer comprised of a drug deposition and a carbonized or densified layer formed from the drug deposition by irradiation on an outer surface of the drug deposition, wherein the carbonized or densified layer does not penetrate through the drug deposition and is adapted to release drug from the drug deposition at a predetermined rate. 1. A drug delivery system , comprising:a medical device having at least one surface region; anda drug layer formed on the at least one surface region, the drug layer comprised of a drug deposition on the at least one surface region and a carbonized or densified layer formed from the drug deposition by irradiation on an outer surface of the drug deposition, wherein the carbonized or densified layer does not penetrate through the drug deposition and is adapted to release drug from the drug deposition at a predetermined rate.2. The drug delivery system of claim 1 , wherein the drug deposition does not include any polymers.3. The drug delivery system of claim 1 , wherein the drug deposition is encapsulated between the carbonized or densified layer and the at least one surface region.4. The drug delivery system of claim 1 , further comprising at least one additional drug layer formed on the first said drug layer claim 1 , the additional drug layer comprised of an additional drug deposition and an additional carbonized or densified layer formed from the additional drug deposition by irradiation on an outer surface of the additional drug deposition.5. The drug delivery system of claim 1 , wherein the at least one surface region is a previously applied drug layer.6. The drug delivery system of claim 1 , wherein the irradiation is gas-cluster ion beam irradiation.7. The drug delivery system of claim 1 , wherein the irradiation is Neutral Beam irradiation derived from a gas-cluster ion beam.8. The drug delivery system of claim 1 , wherein the ...

Absorbable Iron-based Alloy Medical Device Implant

An absorbable iron-based alloy medical device implant, comprising an iron-based alloy substrate () and a degradable polymer () provided on a surface of an iron-based alloy substrate (), and a zinc-containing protective member () provided on the surface of the iron-based alloy substrate (). The zinc-containing protective member () is either a zinc compound or a mixture comprising the zinc compound and at least one of a phosphate-containing compound, a degradable binder, or a water-soluble binder. The weight ratio of the zinc compound in the mixture is ≥20% and <100%. The zinc-containing protective member () can delay corrosion of the iron-based alloy substrate () during an early stage of medical device implantation. The iron-based alloy substrate () is essentially corrosion-free during the early stage of medical device implantation, and is therefore able to satisfy clinical requirements of mechanical performance during the early stage of medical device implantation. 1. An absorbable iron-based alloy medical device implant , comprising an iron-based alloy substrate and a degradable polymer disposed on the surface of the iron-based alloy substrate , wherein the medical device further comprises a zinc-containing protector disposed on the surface of the iron-based alloy substrate; the zinc-containing protector is a zinc compound , or a mixture of the zinc compound and a component selected from the group consisting of a phosphate radical-containing compound , a degradable adhesive or a water-soluble adhesive; and the weight percentage of the zinc compound in the mixture is greater than or equal to 20 percent and less than 100 percent.2. The absorbable iron-based alloy medical device implant according to claim 1 , wherein the zinc-containing protector covers the surface of the iron-based alloy substrate claim 1 , and the degradable polymer covers at least part of the surface of the zinc-containing protector.3. The absorbable iron-based alloy medical device implant ...

ACID FUNCTIONALISED COATED MEDICAL DEVICE AND METHOD OF COATING SUCH A DEVICE

A medical device such as a stent () or medical balloon () is functionalised prior to coating with a bioactive material (), specifically by acidification or basification the contact surface or surfaces () of the medical device. Functionalisation with subsequent coating of bioactive agent directly onto the functionalised surface provides a significantly more consistent and reliable coating of bioactive agent on a medical device without requiring containment or time release devices. 1. A method of coating a medical device having a structure for implantation or disposition inside a patient , the structure including at least one surface for coating , the method including the steps of:functionalising the at least one surface of the structure by subjecting the at least one surface to acidification by acrylic acid or propionic acid to form at least one functionalised surface; andapplying a material coating directly on so as to overlie the at least one functionalised surface of the medical device, the coating being or including a conjugate base where the surface has been subjected to acidification.2. A method according to claim 1 , wherein the at least one surface of the medical device is functionalised by acrylic acid acidification.3. A method according to claim 1 , wherein the at least one surface of the medical device is functionalised by acrylate basification.4. A method according to claim 1 , wherein the conjugate base is a conjugate base component of acrylic acid or propionic acid.5. A method according to claim 1 , wherein the step of functionalising the at least one surface causes an increase in acidic polar components at the at least one surface.6. A method according to claim 1 , wherein the surface is treated with plasma during the step of functionalising the at least one surface by acidification.7. A method according to claim 1 , wherein the coating:a) consists of or is principally of bioactive material;b) is or includes a therapeutic substance;c) is or includes an ...

DRUG ELUTING STENT

Devices and methods for treating ischemia and reperfusion injury (IRI) are configured for sustained-release of anti-proliferative drug into the wall of a blood vessel (to prevent in-stent stenosis), and for sustained-release of leptin antagonist into the lumen to be carried by the blood and be uptaken by tissue cells that were subjected to IRI. 1. A drug eluting stent for treating ischemia and reperfusion injury , comprising a structural framework configured to be deployed in a blood vessel , the structural framework having an outer surface and an inner surface;wherein said outer surface is configured to enable sustained-release of antiproliferative drug and said inner surface is configured to enable sustained-release of a leptin antagonist.2. The drug eluting stent according to claim 1 , wherein upon deployment of the stent in said blood vessel claim 1 , said outer surface abut the blood vessel wall and said inner surface is in contact with blood flowing through the vessel.3. The drug eluting stent according to claim 1 , wherein said structural framework comprises a plurality of outer surface reservoirs containing a sustained-release composition of said antiproliferative drug and a plurality of inner surface reservoirs containing a sustained-release composition of said leptin antagonist.4. The drug eluting stent according to claim 3 , wherein said outer surface reservoirs and said inner surface reservoirs are configured as pits located in said outer surface and said inner surface claim 3 , respectively.5. The drug eluting stent according to claim 3 , wherein said outer surface reservoirs comprise a layer coating the outer surface of said structural framework.6. The drug eluting stent according to claim 3 , wherein said inner surface reservoirs are configured as elongated slits extending along said struts.7. The drug eluting stent according to claim 1 , wherein said structural framework comprises a network of elongated struts.8. The drug eluting stent according to ...

Sensors for continuous analyte monitoring, and related methods

Sensor devices including dissolvable tissue-piercing tips are provided. The sensor devices can be used in conjunction with dissolvable needles configured for inserting the sensor devices into a host. Hardening agents for strengthening membranes on sensor devices are also provided. Methods of using and fabricating sensor devices are also provided.

OPTICAL TECHNIQUE FOR COATING CHARACTERIZATION

The present invention generally relates to methods for determining the presence and distribution of a polarization active material present in a coating. In one embodiment, the coating is present on an implantable device, for example an implantable stent. 1. A method for determining a distribution of a first polarization active compound in a coating , comprising:utilizing optical microscopy to obtain images at a plurality of planes at differing axial positions between an upper and a lower boundary of the coating;measuring a distribution of polarization activity within each of the images, wherein the distribution is based on a distribution in polarization of light within the plurality of images;constructing a three dimensional distribution based on the distribution of polarization active material within each of the plurality of images; anddetermining the distribution of the first polarization active compound in the coating based on the three dimensional polarization activity distribution.2. The method of claim 1 , wherein the first polarization active compound is a crystalline taxane polymorph.3. The method of claim 2 , wherein the crystalline taxane polymorph is a crystalline paclitaxel polymorph.4. The method of claim 3 , therein coating is a coating on an implantable device.5. The method of claim 4 , therein the implantable device is selected from the group consisting of a stent and a balloon.6. The method of claim 5 , wherein the stent is a vascular stent.7. The method of claim 1 , wherein the coating consists essentially of the first polarization active compound and wherein the first polarization active compound is a drug.8. The method of claim 7 , wherein the drug of a taxane.9. The method of claim 8 , wherein the taxane is paclitaxel.10. The method of claim 1 , wherein the coating is free of a polymeric or non-polymeric carrier material.11. The method of claim 1 , further comprising determining a distribution of a second polarization active compound in the ...

SURFACE SEALING FOR IMPLANTS

The present invention relates to an implant for insertion in a body lumen, wherein at least a portion of the surface is arranged to contact a wall of the body lumen and/or bodily fluid flowing through the lumen when the implant is inserted in the body lumen. The abovementioned portion of surface is covered with a surface sealing which is designed to dissolve within about 30 seconds when inserting the implant in the body lumen, such that this portion of surface is exposed to the body lumen. The present invention also relates to a method of manufacturing an implant as above described, comprising the steps of obtaining an implant with a surface; providing at least a portion of such surface with target characteristics; and covering such at least a portion of surface with a surface sealing to preserve the target characteristics. The present invention also refers to an implant set comprising an implant as defined and to a use of such an implant for treating an animal or a human body, wherein the treatment procedure comprises dissolving the surface sealing covering at least a portion of a surface of the implant by flushing the surface with a dissolving solution. 1. An implant for insertion in a body lumen ,the implant comprising a surface, at least a portion of the surface being arranged to contact a wall of the body lumen and/or bodily fluid flowing therethrough when the implant is inserted in the body lumen,whereinthe at least a portion of the surface is covered with a surface sealing which is soluble when inserting the implant in the body lumen, such that the at least a portion of the surface is exposed to the body lumen, and the surface sealing preferably is dissolvable within 30 seconds.2. (canceled)3. The implant of claim 1 , wherein the surface sealing comprises claim 1 , or consists of claim 1 , a soluble carbohydrate claim 1 , a soluble polymer claim 1 , a soluble ionic compound claim 1 , or a combination thereof.4. The implant of claim 3 , whereinthe soluble ...

MEDICAL DEVICE

The disclosed medical device has high visibility on non-woven fabric having a color such as green, blue, or the like, excellent identifiability from other medical devices having colors such as green, blue, or the like, and also a high adhesion property and strength of a coating. The medical device comprises an elongated body and a resin layer covering at least a proximal portion of the elongated body. The resin layer is comprised of a first layer which includes a first fluororesin, an organic pigment and titanium oxide, and a second layer which is formed on the first layer and includes a second fluororesin. 1. A medical device comprising:an elongated body possessing a distal-most end and a proximal-most end, the elongated body possessing a distal portion extending from the distal-most end of the elongated body towards the proximal-most end of the elongated body;a first resin layer covering the proximal portion of the elongated body and not covering the distal portion of the elongated body, the first resin layer including a first fluororesin, organic pigment, and titanium oxide;a second resin layer covering the first resin layer and not covering the distal portion of the elongated body, the second resin layer including a second fluororesin; anda composition of the first resin layer being different from a composition of the second resin layer.2. The medical device according to claim 1 , wherein the first and second resin layers each possesses a distal-most end that is spaced proximally from the distal-most end of the elongated body by a distance of at least 300 mm.3. The medical device according to claim 1 , further comprising a wire member wound in a spiral shape in surrounding relation to the distal portion of the elongated body claim 1 , the wire member that is wound in the spiral shape possessing a proximal-most end claim 1 , the first and second resin layers each possessing a distal-most end spaced proximally from the proximal-most end of the wire member that is ...

METHOD FOR COATING SURGICAL INTRUMENTS

A coating and devices using the coating are provided. The coating is applied in liquid form and dried or otherwise cured to form a durable adherent coating resistant to high temperatures and having optional hydrophobic properties. The coating formulation contains an aqueous formulation of silica, one or more fillers, and sufficient base, (e.g., potassium hydroxide), to have a pH exceeding about 10.5 during at least part of the formulation process. The formulation may contain a compound(s) that affects surface free energy, energy to make the cured coating hydrophobic. Such compounds include silanes containing halogens (e.g., fluorine or chlorine) and in particular silanes containing one or more hydrolyzable groups attached to at least one silicon atom and a group containing one or more halogens (e.g., chlorine or fluorine). A medical instrument (e.g., electrosurgical instrument) may be at least partially covered by a coating using the formulation. 1. An electrosurgical instrument comprising:a metal surface portion including at least one edge; and, silica;', 'at least one inorganic filler; and,', 'a strong base in an amount so that the coating formulation has a pH of at least 10.5 during at least part of a formulation process., 'a coating provided on at least a portion of the metal surface portion of the electrosurgical instrument so that at least a portion of the at least one edge of the metal surface has an impedance from the electrosurgical instrument to tissue of less than about 5,000 ohms, wherein the coating is defined by a coating formulation including2. An electrosurgical instrument as recited in claim 1 , wherein said at least a portion of said at least one edge of the metal surface portion is exposed through said coating.3. An electrosurgical instrument as recited in claim 2 , wherein at least part of the coating is between about 0.001 and 0.1 inches thick.4. An electrosurgical instrument as recited in claim 1 , wherein at least part of the coating is ...

Coated orthodontic crimpable auxiliary and method for making the same

An orthodontic crimpable auxiliary, having all or portions of a surface of the crimpable auxiliary configured to contact an archwire after crimping coated with diamond particles in a metal matrix. The metal matrix can be nickel.

Vanadium Compounds as Therapeutic Adjuncts for Cartilage Injury and Repair

A method for repairing an injury of cartilage in a patient by local administration of an organovanadium agent or use of an implantable device for delivery of an organovanadium agent. Implantable devices containing an organovanadium agent and methods of making these implantable devices are also disclosed.

PDLLA Stent Coating

An amorphous PDLLA stent coating for drug delivery is disclosed.

METHOD FOR ELECTROSTATIC COATING OF A MEDICAL DEVICE

A method for electrostatic coating of medical devices such as stents and balloons is described. The method includes applying a composition to a polymeric component of a medical device which has little or no conductivity. The polymeric component could be a material from which the body or a strut of the stent is made or could be a polymeric coating pre-applied on the stent. The polymeric component could be the balloon wall. A charge can then be applied to the polymeric component or the polymeric component can be grounded. Charged particles of drugs, polymers, biobeneficial agents, or any combination of these can then be electrostatically deposited on the medical device or the coating on the medical device. One example of the composition is iodine, iodine, iodide, iodate, a complex or salt thereof which can also impart imaging capabilities to the medical device. 1. A method of coating a stent , the method comprising:mounting a stent on a support structure, the stent comprising a polymeric component;applying a treatment material comprising a surfactant, and a halogen, halogen salt, halogen complex or a moiety including a halide, to the polymeric component;grounding or applying a charge to the polymeric component; andapplying a charged drug to the polymeric component such that the drug is electrostatically deposited on the stent or the balloon;wherein the surfactant is Vitamin E TPGS, Ascorbyl palmitate, gelatin, lecithin, egg yolk phopholipid, phosphatidylcholine, polyethylene glycol-phosphatidyl ethanolamine conjugate, polyethylene glycol-phospholipid conjugates, and combinations thereof.2. The method of claim 1 , wherein the treatment material is iodine claim 1 , iodide claim 1 , iodate claim 1 , or a complex or a salt thereof.3. The method of claim 1 , wherein the treatment material is dissolved in a solvent.4. The method of claim 1 , wherein the treatment material consist of iodine claim 1 , iodide claim 1 , iodate claim 1 , or a complex or salt thereof dissolved in ...

Angiogenic Factors

The disclosure relates to methods for obtaining angiogenic factors, as well as to methods of treating cardiovascular disease and methods for stimulating angiogenesis. 1. (canceled)2. A method for obtaining an angiogenic factor from one or more cells comprising:i) ;ii) attaching one or more cells which produce an angiogenic factor to a structure obtained by thermally induced phase separation;iii) culturing the one or more attached cells in appropriate conditions for the cells to produce the angiogenic factor; andiv) isolating the angiogenic factor produced by the cells.3. The method of wherein the structure is a coating on a substrate.4. The method of wherein the substrate is a cell culture plate or flask.5. The method of wherein the cells are Human Adipose Derived Stem Cells (ADMSCs).6. The method of wherein the angiogenic factor is Vascular Endothelial Growth Factor (VEGF).7. The method of wherein the isolating is by collection of the liquid in which the cells are cultured.8. The method of wherein the thermally induced phase separation comprises:i) coating the substrate with a polymer and a solvent;ii) quenching the substrate having the polymer and solvent coating in a quenching fluid; andiii) freeze-drying the coating to obtain the substrate coated with the structure.9. The method of wherein the polymer is PLGA.10. The method of wherein the solvent is dimethyl carbonate.11. The method of wherein the quenching fluid is liquid nitrogen.122. The method of wherein the method is performed in vitro.13. (canceled)14. A method for obtaining Vascular Endothelial Growth Factor (VEGF) from one or more Adipose Derived Stem Cells (ADMSCs) comprising:i) attaching one or more ADMSCs to a coating on a tissue culture plate or flask formed by thermally induced phase separation;ii) culturing the ADMSCs in appropriate conditions for the cells to produce VEGF; andiii) isolating the VEGF produced by the cells.15. A method of treating cardiovascular disease comprising:administering to a ...

Drug releasing coatings for balloon catheters

Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups.

BIORESORBABLE ENDOLUMINAL PROSTHESIS FOR MEDIUM AND LARGE VESSELS

An endoluminal prosthesis includes an implantable scaffold and/or stent substrate which is convertible from a compressed first geometric shape to a radially dilated dimensionally stable second tubular second geometric shape, the scaffold and/or stent substrate comprising a bioresorbable zinc alloy, the zinc alloy including at least at least four alloying elements selected from the group consisting of silver (Ag) in an amount of about 1.0 wt. % to about 6.0 wt. %, manganese (Mn) in an amount of about 0.1 wt. to about 2.0 wt. %, zirconium (Zr) in an amount of about 0.05 wt. % to about 1.0 wt. %, copper (Cu) in an amount of about 0.5 wt. % to about 1.2 wt. %, and optionally titanium (Ti) in an amount of 0 to about 0.4 wt. %, with the balance of the alloy being zinc and incidental impurities. 1. An endoluminal prosthesis comprising:an implantable stent and/or scaffold substrate which is convertible from a compressed first tubular geometric shape to a radially dilated dimensionally stable second tubular geometric shape, the stent substrate comprising a bioresorbable zinc alloy, the zinc alloy including at least four alloying elements selected from the group consisting of silver (Ag) in an amount of about 1.0 wt. % to about 6.0 wt. %, manganese (Mn) in an amount of about 0.1 wt. to about 2.0 wt. %, zirconium (Zr) in an amount of about 0.05 wt. % to about 1.0 wt. %, copper (Cu) in an amount of about 0.5 wt. % to about 1.2 wt. %, and optionally titanium (Ti) in an amount of 0 to about 0.4 wt. %, with the balance of the alloy being zinc and incidental impurities.2. The endoluminal prosthesis of claim 1 , wherein the zinc alloy has an ultimate tensile strength of greater than about 250 MPa.3. The endoluminal prosthesis of claim 1 , wherein the zinc alloy has an elongation to failure greater than about 25%.4. The endoluminal prosthesis of claim 1 , wherein zinc alloy has substantially uniform microstructure with a Zn grain size of about 0.1 μm to about 10 μm and a plurality of ...

Surface modified structure for improving hemocompatibility of biomedical metallic substrates

The present invention relates to a surface modification method for improving the hemocompatibility of a biomedical metallic substrate, comprising: fixing a sulfur-containing and nitrogen-containing monolayer film on the surface of oxide layer of the biomedical metallic substrate by molecular self-assembly. The surface modification improves the hydrophilicity and hemocompatibility of the biomedical metallic substrate in contact with the blood, and ensures that the biomedical metallic substrate is non-toxic to the endothelial cells.

SYSTEMS AND METHODS FOR SELECTIVE COATING REMOVAL FOR RESORBABLE METAL MEDICAL DEVICES

The invention relates to self-assembled orgaosilane coatings for resorbable medical implant devices. The coatings can be prepared from coating compositions containing organosilane and can be applied to metal or metal alloy substrates. Prior to applying the coatings, the surfaces of the substrates can be pretreated. The coatings can be functionalized with a binding compound that is coupled with an active component. The coatings can be selectively removed, e.g., patterned, to expose portions of the uncoated substrate. Selecting different patterns can provide the ability to regulate or control various properties, such as, corrosion and hydrogen generation. 1. A medical implant device , comprising:a substrate selected from the group consisting of magnesium and magnesium alloy, having a first surface and an opposing second surface;a self-assembled organosilane-containing coating applied to at least one of the first and second surfaces; and 'one or more areas of selective removal of the coating from the substrate.', 'a pattern applied to the coating on at least one of the first and second surfaces, the pattern comprising2. The device of claim 1 , further comprising a binding compound combined with the coating.3. The device of claim 2 , further comprising an active component coupled to the binding compound.4. The device of claim 1 , further comprising a pretreatment applied to at least one of the first and second surfaces claim 1 , and the coating applied to the pretreatment.5. The device of claim 1 , wherein a first portion of the pattern has a first configuration and a second portion of the pattern has a different claim 1 , second configuration.6. The device of claim 1 , wherein the one or more areas of selective removal is effective to increase the corrosion rate of the substrate.7. A method of forming a patterned coating on a medical implant device claim 1 , comprising:obtaining an uncoated substrate having a top surface and an opposing bottom surface;preparing a ...

Biliary Stent

The present disclosure provides an endoprosthesis where a preferably polymeric coating has a number of surface features such as protrusions or textures that are arranged in a micropattern. The endoprosthesis optionally has an expanded state and a contracted state, and in some cases includes a stent with a polymeric coating attached to an outer surface of the stent. The stent may have an inner surface defining a lumen, an outer surface, and a stent thickness defined between the inner surface and outer surface. The stent may comprise a plurality of surface textures extending from the stent surfaces, wherein the textures are arranged in a macropattern. 1. A stent device for placement in a body lumen comprising:a tubular member having an interior surface and an exterior surface wherein at least one of the surfaces comprises one or more hierarchical patterns;at least one of the one or more hierarchical patterns comprising at least a first texture and at least a second texture;the at least first texture and the at least second texture configured to develop a Wenzel interface and a Cassie interface when in contact with a wet surface.2. The stent device of wherein the one or more hierarchical patterns are further configured to create one of at least a cell migration promoting surface or an anti-fouling surface claim 1 , or both.3. The stent device of wherein the cell migration promoting surface is configured to selectively promote cell migration of one cell type and inhibit cell migration of a second cell type.4. The stent device of wherein the hierarchical pattern comprises a first distinct region claim 1 , a second distinct region claim 1 , and a third distinct region claim 1 , the distinct regions disposed about the tubular member;the first distinct region comprising a body tissue adhesive surface;the second distinct region comprising a cell migration promoting surface; andthe third distinct region comprising an anti-fouling surface.5. The stent device of wherein the ...

CO-CRYSTALS, METHOD AND APPARATUS FOR FORMING THE SAME

Disclosed herein is a method and apparatus for synthesizing co-crystals from the vapor phase without the need for liquid solvent. Also disclosed herein are co-crystals formed from the vapor phase, substrates coated with said co-crystals, pharmaceutical compositions thereof and apparatuses for producing said co-crystals. 1. A method of forming a co-crystal of an organic compound and a coformer comprising:(a) subliming and/or evaporating the organic compound optionally in the presence of an organic compound carrier gas to form a organic compound vapor;(b) subliming and/or evaporating the coformer optionally in the presence of a coformer carrier gas to form a coformer vapor;(c) mixing the organic compound vapor and the coformer vapor, optionally in the presence of a mixing gas, to form a vapor mixture, wherein the vapor mixture comprises a molar ratio of the organic compound and the coformer of 10:1 to 1:10; and(d) condensing the vapor mixture onto a substrate to form the co-crystal;wherein:the co-crystal comprises the organic compound and the coformer hydrogen bonded together, optionally in a ratio of 1:3 to 3:1;the organic compound is sublimed at a temperature that is 10° C. to 100° C. above its onset of sublimation, as determined by thermogravimetric analysis (“TGA”);the substrate is at a temperature of −50° C. to 50° C.;and the co-crystal is stable at 25° C., characterized by differential scanning calorimetry, microscopy, X-ray diffraction, or a combination thereof.2. The method of claim 1 , wherein the substrate is coated with the co-crystal during step (d).3. The method of or claim 1 , wherein the substrate comprises quartz claim 1 , glass claim 1 , metal claim 1 , plastic claim 1 , ceramic claim 1 , or combinations thereof.4. The method of any one of - claim 1 , wherein the substrate is temperature-controlled.5. The method of any one of - claim 1 , wherein the molar ratio of organic compound to coformer in the vapor mixture is 1:3 to 1:5.6. The method of claim 5 ...

SYSTEMS, DEVICES, AND METHODS INCLUDING IMPLANTABLE DEVICES WITH ANTI-MICROBIAL PROPERTIES

Systems, devices, methods, and compositions are described for providing an actively controllable implant configured to, for example, monitor, treat, or prevent microbial growth or adherence to the implant. 165.-. (canceled)66. An insertable device , comprising:a body structure having an outer surface and an inner surface defining one or more fluid-flow passageways;wherein at least one of the outer surface, or the inner surface of the body structure includes at least one actively controllable anti-microbial nanostructure.67. The insertable device of claim 66 , further comprising at least one sensor configured to detect one or more microorganisms present proximate to the body structure.68. The insertable device of claim 66 , wherein at least one anti-microbial nanostructure includes at least one high aspect ratio nanofibrillar structure.69. The insertable device of claim 66 , wherein at least one anti-microbial nanostructure includes at least one nanoscale projection.70. The insertable device of claim 69 , wherein the at least one nanoscale projection includes at least one of a nanoscale irregularity claim 69 , nanoscale elongation claim 69 , nanoscale valley claim 69 , or nanoscale ridge.71. (canceled)72. The insertable device of claim 66 , wherein at least one of the outer surface or inner surface includes at least one switchable surface.73. The insertable device of claim 72 , wherein the at least one switchable surface is configured to alter the liquid-solid contact angle of the at least one actuatable anti-microbial nanostructure.74. The insertable device of claim 72 , wherein the at least one switchable surface includes poly(dimethylsiloxane).75. The insertable device of claim 66 , wherein the at least one anti-microbial nanostructure is configured to inhibit at least one of microbial movement claim 66 , microbial attachment claim 66 , microbial growth claim 66 , or microbial persistence on the surface of the body structure.76. The insertable device of claim 66 , ...

Cross-linked fatty acid-based biomaterials

Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided.

DRUG RELEASING COATINGS FOR MEDICAL DEVICES

Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups. 1. A balloon catheter for delivering a therapeutic agent to target site in a blood vessel , the balloon catheter comprising: the therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, beta-lapachone, biologically active vitamin D, and combinations thereof; and', 'the at least one first additive comprises a PEG fatty ester selected from the group consisting of PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, PEG sorbitan palmitates, and combinations thereof; and, 'a coating layer overlying an exterior surface of a balloon, the coating layer comprising a therapeutic agent and at least one first additive, whereina biocompatible polymer.2. The balloon catheter of claim 1 , wherein the biocompatible polymer is present in an adherent layer.3. The balloon catheter of claim 2 , wherein the adherent layer is positioned between the coating layer and the exterior surface of the balloon.4. The balloon catheter of claim 1 , wherein the biocompatible polymer is selected from the group consisting of polyolefins claim 1 , polyisobutylene claim 1 , ethylene-1-olefin copolymers claim 1 , acrylic polymers claim 1 , ...

Encapsulated Drug Compositions and Methods of Use Thereof

Various aspects of the present disclosure provide compositions, coatings and implantable devices including a drug and an excipient. In certain embodiments the excipient and the drug are present at a weight ratio of between 10 to 1 and 1 to 10 drug to excipient. In certain other embodiments, the excipient and the drug form particles in which the drug is encapsulated by the excipient. Other aspects of the disclosure provide methods of manufacturing and using such compositions, coatings and implantable devices. 1. A medical device comprising:a base structure having a surface, anda coating on the surface comprising a drug and an excipient, wherein the coating comprises a plurality of particles comprising the drug encapsulated by the excipient and wherein the excipient is selected from the group consisting of a gallate containing compound, epi gallo catechin gallate, tannic acid and epi catechin gallate.2. The medical device of claim 1 , wherein the drug and excipient are present at a weight ratio of between 10 to 1 and 1 to 10 drug to excipient.3. The medical device of claim 1 , wherein the excipient is selected from a group consisting of epi gallo catechin gallate and tannic acid and epi catechin gallate.4. The medical device of claim 3 , wherein the excipient is tannic acid.5. The medical device of claim 3 , wherein the excipient is epi gallo catechin gallate.6. The medical device of claim 1 , wherein the coating consists essentially of the excipient and the drug.7. The medical device of claim 1 , wherein the drug is selected from the group consisting of an immunosuppressive agent claim 1 , an antiproliferative agent claim 1 , a microtubule stabilizing agent claim 1 , a restenosis-inhibiting agent claim 1 , and an inhibitor of the mammalian target of rapamycin.8. The medical device of claim 7 , wherein the drug is a taxane compound.9. The medical device of claim 8 , wherein the taxane compound is paclitaxel.10. The medical device of claim 7 , wherein the drug is a ...

COMPOUNDS AND COMPOSITIONS FOR DRUG RELEASE

The invention relates to compounds that include biologically active agents (e.g., compounds according to any of formulas (I) and (I-A) that can be used for effective drug release, e.g., as coatings for medical devices. Use of these compounds in the coating of surfaces can allow for long-term drug release as well as imparting uniform coatings with little phase separation compared to, e.g., the parent biologically active agent. 1. An article comprising a coated surface , wherein said coated surface comprises a compound having a structure according to formula (I):{'br': None, 'sup': 1', '1', '2', '1, 'sub': 'm', 'Bio-Link-(Bio-R)\u2003\u2003(I),'}or a pharmaceutically acceptable salt thereof, wherein{'sup': '1', 'Biois formed from a biologically active agent;'}m is 1, 2, 3, 4, or 5;{'sup': 2', '2', '1, 'each Biois absent or independently formed from a biologically active agent, and wherein each Bio, when present, comprises a covalent bond to Link;'}{'sup': 1', '2, 'Ris present only when Biois absent and is a terminal group selected from the group consisting of H, OH, optionally substituted C1-C6 alkyl, and optionally substituted C1-C6 alkoxy;'}{'sup': '1', 'Linkis an oligomeric organic, organosilicon, or organosulfone segment having a molecular weight between 60 and 2000 Daltons.'}2. The article of claim 1 , wherein said compound has a structure according to formula (I-A) claim 1 ,{'br': None, 'sup': 1', '1', '2', '1, 'Bio-Link-Bio-R\u2003\u2003(I-A),'}or a pharmaceutically acceptable salt thereof, wherein{'sup': '1', 'Biois formed from a biologically active agent;'}{'sup': '2', 'Biois absent or formed from a biologically active agent;'}{'sup': '1', 'R, when present, is H, OH, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 alkoxy; and'}{'sup': '1', 'Linkis an oligomeric organic, organosilicon, or organosulfone segment having a molecular weight between 60 and 2000 Daltons.'}3. The article of or claim 1 , wherein Biois absent.4. The article of or ...

MEDICAL DEVICE FOR BONE IMPLANT AND METHOD FOR PRODUCING SUCH A DEVICE

A bone implantable medical device made from a biocompatible material, preferably comprising titania or zirconia, has at least a portion of its surface modified to facilitate improved integration with bone. The implantable device may incorporate a surface infused with osteoinductive agent and/or may incorporate holes loaded with a therapeutic agent. The infused surface and/or the holes may be patterned to determine the distribution of and amount of osteoinductive agent and/or therapeutic agent incorporated. The rate of release or elution profile of the therapeutic agent may be controlled. Methods for producing such a bone implantable medical device are also disclosed and employ the use of accelerated Neutral Beam irradiation, wherein the Neutral Beam is derived from an accelerated gas cluster ion beam irradiation for improving bone integration. 1. A method of modifying a surface of a bone-implantable medical device comprising the steps of:coating at least a first portion of the surface of the medical device with an osteoinductive agent to form a coated surface region; andfirst irradiating at least a portion of the coated surface region with a first accelerated Neutral Beam.2. The method of claim 1 , wherein the first irradiating step forms a shallow surface and subsurface layer comprising embedded molecules and/or dissociation products of the osteoinductive agent.3. The method of claim 1 , wherein the first accelerated Neutral Beam is derived from a first gas cluster ion beam and further wherein the shallow surface and subsurface layer is an infused surface layer.4. The method of claim 1 , wherein the osteoinductive agent comprises claim 1 , separately or in combination claim 1 , any of the materials from the group consisting of: a nutrient material claim 1 , tricalcium phosphate claim 1 , hydroxyapatite claim 1 , Bioglass 45S5 claim 1 , Bioglass 58S claim 1 , a bone growth-stimulating agent claim 1 , a growth factor claim 1 , a cytokine claim 1 , a TGF-β protein ...

IMPLANTABLE GRAPHENE MEMBRANES WITH LOW CYTOTOXICITY

Two-dimensional materials can be formed into enclosures for various substances and a substrate layer can be provided on an outside and/or on an inside of the enclosure, wherein the enclosure is not cytotoxic. The enclosures can be exposed to an environment, such as a biological environment (in vivo or in vitro), where the fibrous layer can promote vascular ingrowth. One or more substances within the enclosure can be released into the environment, one or more selected substances from the environment can enter the enclosure, one or more selected substances from the environment can be prevented from entering the enclosure, one or more selected substances can be retained within the enclosure, or combinations thereof. The enclosure can, for example, allow a sense-response paradigm to be realized. The enclosure can, for example, provide immunoisolation for materials, such as living cells, retained therein. 1. An enclosure comprising a compartment and a wall separating the compartment from an environment external to the compartment , wherein the wall comprises:a perforated graphene-based material layer anda substrate layer affixed directly or indirectly to the perforated graphene-based material,and wherein the enclosure is not cytotoxic when implanted into a subject.2. The enclosure of claim 1 , wherein the substrate layer comprises track-etched polyimide.3. The enclosure of claim 1 , wherein the substrate layer comprises a fibrous layer comprising a plurality of polymer filaments.4. The enclosure of claim 1 , wherein the compartment is in fluid communication with the external environment.5. The enclosure of claim 1 , wherein at least a portion of the wall is from about 5 nm to about 1 μm thick.6. The enclosure of claim 1 , further comprising at least one substance encapsulated within the compartment.7. The enclosure of claim 6 , wherein two or more substances are encapsulated within the compartment.8. The enclosure of claim 6 , wherein the substance comprises one or more ...

COATING COMPOSITION FOR SKIN-CONTACTING SURFACE OF ELASTOMERIC ARTICLES AND ARTICLES CONTAINING THE SAME

The invention described herein relates to a therapeutic, moisturizing coating composition for elastomeric articles which is applied directly onto the skin-contacting surface of the article as part of the manufacturing process. The coating composition is thermally stable and subsequently hydrates when contacted with a moisturized skin surface to convert into a liquid “lotion” form during wearing of the article. The coating composition provides therapeutic benefits to the wearer's skin as a result of wearing the article, such as improved skin moisturization, softness of feel, improved skin elasticity and firmness, and reduced redness and irritation. The invention is particularly useful in medical gloves, including examination and surgical gloves. 1. An elastomeric article comprising: an elastomeric layer; and 'at least two polyhydric alcohol moisturizers;', 'a coating formed from a coating composition, the coating composition comprisingwherein the coating is water-soluble and hydratable upon contact with skin.2. The elastomeric article according to claim 1 , wherein the coating composition further comprises an acidic pH adjuster.3. The elastomeric article according to claim 2 , further comprising sodium citrate claim 2 , wherein sodium citrate acts as a buffer to the acidic pH adjuster.4. The elastomeric article according to claim 2 , wherein the acidic pH adjuster comprises an organic acid.5. The elastomeric article according to claim 4 , wherein the acidic pH adjuster is citric acid.6. The elastomeric article according to claim 5 , wherein prior to application to the elastomeric layer claim 5 , citric acid is present in the coating composition in an amount of up to about 0.5% by weight of the coating composition.7. The elastomeric article according to claim 3 , wherein prior to application to the elastomeric layer claim 3 , sodium citrate is present in the coating composition in an amount of up to about 2.0% by weight of the coating composition.8. The elastomeric ...